AUTHOR INDEX TO VOLUME 60

Abbott DH. *See* Saltzman W
Abraini JH. *See* David HN
Achim AM. *See* Lepage M
Adams JM. *See* Joffe H
Adams P. *See* Fyer AJ
Adamson JJ. *See* Faraone SV
Adler CM. *See* Patel NC
Ahern TH. *See* Mitchell HA
Ahveninen J, Jääskeläinen IP, Osipova D, Huttunen MO, Ilmoniemi RJ, Kaprio J, Lönnqvist J, Manninen M, Pakarinen S, Therman S, Näätänen R, Cannon TD. Inherited Auditory-Cortical Dysfunction in Twin Pairs Discordant for Schizophrenia, 612
Aleardi M. *See* Seidman LJ
Alexopoulos GS. The Vascular Depression Hypothesis: 10 Years Later, 1304
Alleva E. *See* Branchi I
Almasy L. *See* Walss-Bass C
Aloe L. *See* Branchi I
Alpert J. *See* Fraguas R Jr
Althoff RR. *See* Boomsma DI
Althoff RR, Rettew DC, Faraone SV, Boomsma DI, Hudziak JJ. Latent Class Analysis Shows Strong Heritability of the Child Behavior Checklist–Juvenile Bipolar Phenotype, 903
Altshuler LL. *See* Keck PE Jr
Alva G. *See* DeBattista C
Amat J. *See* Wiedenmayer CP
Amin F. *See* Tseng KY
Anderle MJ. *See* Larson CL
Anderson EJ. *See* Fan X
Anderson GM. *See* Tang Y; Wiedenmayer CP
Anderson KC, Insel TR. The Promise of Extinction Research for the Prevention and Treatment of Anxiety Disorders, 319
Andreasen NC. *See* White T
Andrieux A, Salin P, Schweitzer A, Bégou M, Pachoud B, Brun P, Gory-Fauré S, Kujala P, Suaud-Chagny M-F, Höfle G, Job D. Microtubule Stabilizer Ameliorates Synaptic Function and Behavior in a Mouse Model for Schizophrenia, 1224
Andrzejewski ME. *See* Berridge CW
Angold A. *See* Brotman MA
Ansseau M. *See* David HN
Arai M. *See* Fukuda Y
Arinami T. *See* Fukuda Y
Arnsten AFT. *See* Berridge CW
Åsberg M. *See* Rydmark I; Zaboli G
Asherson P. *See* Brookes KJ
Astur RS. *See* Johnson MR
Aubry J-M. *See* Delorme R

Baaré W. *See* Glenthoj BY
Baas JMP. *See* Grillon C; Grillon C
Babushkin I. *See* Levine J
Backhaus J, Junghanns K, Born J, Hohaus K, Faasch F, Hohagen F. Impaired Declarative Memory Consolidation During Sleep in Patients With Primary Insomnia: Influence of Sleep Architecture and Nocturnal Cortisol Release, 1324
Bae JN, MacFall JR, Krishnan KRR, Payne ME, Steffens DC, Taylor WD. Dorsolateral Prefrontal Cortex and Anterior Cingulate Cortex White Matter Alterations in Late-Life Depression, 1356
Balkissoon R. *See* Maeda K
Bansal R. *See* Wiedenmayer CP
Barad M, Gean P-W, Lutz B. The Role of the Amygdala in the Extinction of Conditioned Fear, 322
Barch DM. *See* Sheline YI
Barro M. *See* Vollenweider FX
Bates ME. *See* Voelbel GT
Baud P. *See* Delorme R
Baumer FM, Howe M, Gallelli K, Simeonova DI, Hallmayer J, Chang KD. A Pilot Study of Antidepressant-Induced Mania in Pediatric Bipolar Disorder: Characteristics, Risk Factors, and the Serotonin Transporter Gene, 1005
Becker TM. *See* MacDonald AW III
Bégou M. *See* Andrieux A
Beijsterveldt TC. *See* Boomsma DI
Belanoff J. *See* DeBattista C
Bellgrove MA, Mattingley JB, Hawi Z, Mullins C, Kirley A, Gill M, Robertson IH. Impaired Temporal Resolution of Visual Attention and Dopamine Beta Hydroxylase Genotype in Attention-Deficit/Hyperactivity Disorder, 1039
Belmaker R. *See* Levine J
Benca RM. *See* Schaefer HS
Bernardi G. *See* Centonze D
Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AFT, Kelley AE, Schmeichel B, Hamilton C, Spencer RC. Methylphenidate Preferentially Increases Catecholamine Neurotransmission within the Prefrontal Cortex at Low Doses that Enhance Cognitive Function, 1111
Berson A. *See* Sklan EH
Bersudsky Y. *See* Levine J
Bertolino A, Rubino V, Sambataro F, Blasi G, Latorre V, Fazio L, Caforio G, Petruzzella V, Kolachana B, Hariri A, Meyer-Lindenberg A, Nardini M, Weinberger DR, Scarabino T. Prefrontal-Hippocampal Coupling During Memory Processing Is Modulated by COMT Val158Met Genotype, 1250
Bertschy G. *See* Delorme R
Betancur C. *See* Delorme R
Bhandari R. *See* MacMaster FP
Bhatia T. *See* Talkowski ME
Biederman J. The Evolving Face of Pediatric Mania, 901
Biederman J. *See* Faraone SV; Seidman LJ
Biederman J, Gao H, Rogers AK, Spencer TJ. Comparison of Parent and Teacher Reports of Attention-Deficit/Hyperactivity Disorder Symptoms from Two Placebo-Controlled Studies of Atomoxetine in Children, 1106
Biederman J, Monuteaux MC. Reply, 1166
Biederman J, Monuteaux MC, Mick E, Spencer T, Wilens TE, Klein KL, Price JE, Faraone SV. Psychopathology in Females with Attention-Deficit/Hyperactivity Disorder: A Controlled, Five-Year Prospective Study, 1098
Binder EB. *See* Himmerich H
Birikh KR. *See* Sklan EH
Blair J. *See* Roberson-Nay R
Blankenship A. *See* Wolf SA
Blasey C. *See* DeBattista C
Blasi G. *See* Bertolino A
Blazer DG. *See* Marx CE
Bogdan R, Pizzagalli DA. Acute Stress Reduces Reward Responsiveness: Implications for Depression, 1147
Bolaños CA. *See* Lagace DC
Bondolfi G. *See* Delorme R

0006-3223/06/$32.00
doi:10.1016/S0006-3223(06)01475-2

© 2006 Society of Biological Psychiatry

Booij L, Swenne CA, Brosschot JF, Haffmans PJ, Thayer JF, Van der Does AW. Tryptophan Depletion Affects Heart Rate Variability and Impulsivity in Remitted Depressed Patients with a History of Suicidal Ideation, 507
Boomsma DI. *See* Althoff RR
Boomsma DI, Rebollo I, Derks EM, Beijsterveldt TC, Althoff RR, Rettew DC, Hudziak JJ. Longitudinal Stability of the CBCL-Juvenile Bipolar Disorder Phenotype: A Study in Dutch Twins, 912
Borba CP. *See* Fan X
Boriel DL. *See* Seidman LJ
Born C. *See* Zetzsche T
Born J. *See* Backhaus J; Wagner U
Bottiglieri T. *See* Fraguas R Jr
Bourgeron T. *See* Delorme R
Bouton ME, Westbrook RF, Corcoran KA, Maren S. Contextual and Temporal Modulation of Extinction: Behavioral and Biological Mechanisms, 352
Boyd C. *See* MacMaster FP
Braff DL. *See* Light GA
Branchi I, D'Andrea I, Fiore M, Di Fausto V, Aloe L, Alleva E. Early Social Enrichment Shapes Social Behavior and Nerve Growth Factor and Brain-Derived Neurotrophic Factor Levels in the Adult Mouse Brain, 690
Brand SR. *See* Yehuda R
Brandon NJ. *See* Porteous DJ
Braselton J. *See* Sprouse J
Braus DF. *See* Tost H
Brickman AM, Zimmerman ME, Paul RH, Grieve SM, Tate DF, Cohen RA, Williams LM, Clark CR, Gordon E. Regional White Matter and Neuropsychological Functioning across the Adult Lifespan, 444
Brookes KJ, Chen W, Xu X, Taylor E, Asherson P. Association of Fatty Acid Desaturase Genes with Attention-Deficit/Hyperactivity Disorder, 1053
Brosschot JF. *See* Booij L
Brotman MA, Schmajuk M, Rich BA, Dickstein DP, Guyer AE, Costello EJ, Egger HL, Angold A, Pine DS, Leibenluft E. Prevalence, Clinical Correlates, and Longitudinal Course of Severe Mood Dysregulation in Children, 991
Brown SM. *See* Neumann SA
Brun P. *See* Andrieux A
Bryan HS. *See* Patel NC
Brzustowicz LM. *See* Widom CS, and Brzustowicz LM.
Buchsbaum BR. *See* Buchsbaum MS
Buchsbaum MS, Friedman J, Buchsbaum BR, Chu K-W, Hazlett EA, Newmark R, Schneiderman JS, Torosjan Y, Tang C, Hof PR, Stewart D, Davis KL, Gorman J. Diffusion Tensor Imaging in Schizophrenia, 1181
Buckman JF. *See* Voelbel GT
Buresi C. *See* Delorme R
Burne THJ. *See* Kesby JP
Bush G. *See* Seidman LJ
Butler A. *See* Talkowski ME
Butler PD. *See* Schechter I
Butterfield MI. *See* Marx CE
Buxbaum JD. *See* Ramoz N
Buxbaum SG. *See* Tang Y

Caforio G. *See* Bertolino A
Cain CK. *See* Sotres-Bayon F
Calabrese JR. *See* Youngstrom E
Calabresi P. *See* Centonze D
Calhoun VD. *See* Johnson MR
Camchong J, Dyckman KA, Chapman CE, Yanasak NE, McDowell JE. Basal Ganglia-Thalamocortical Circuitry Disruptions in Schizophrenia During Delayed Response Tasks, 235
Cannon DM, Ichise M, Fromm SJ, Nugent AC, Rollis D, Gandhi SK, Klaver JM, Charney DS, Manji HK, Drevets WC. Serotonin Transporter Binding in Bipolar Disorder Assessed using [^{11}C]DASB and Positron Emission Tomography, 207
Cannon TD. *See* Ahveninen J
Carlson SE. *See* Levant B
Carpenter LL. *See* DeBattista C
Carroll K. *See* Petrakis IL
Carter CS. Re-Conceptualizing Schizophrenia as a Disorder of Cognitive and Emotional Processing: A Shot in the Arm for Translational Research, 1169
Carter CS. *See* MacDonald AW III
Casey B. *See* Durston S
Caviness VS. *See* Seidman LJ
Cecil KM. *See* Patel NC
Centonze D, Costa C, Rossi S, Prosperetti C, Pisani A, Usiello A, Bernardi G, Mercuri NB, Calabresi P. Chronic Cocaine Prevents Depotentiation at Corticostriatal Synapses, 436
Chan H-Y. *See* Liu Y-L
Chang J. *See* Maeda K
Chang KD. *See* Baumer FM
Chang Y-C. *See* Lane H-Y
Chapman CE. *See* Camchong J
Charney D. *See* Rasmusson AM
Charney DS. A Heartfelt Thank You, 793
Charney DS. *See* Cannon DM; Roberson-Nay R
Chen C-H. *See* Liu Y-L
Chen H. *See* Maeda K
Chen J-J. *See* Liu Y-L
Chen P-W. *See* Lane H-Y
Chen W. *See* Brookes KJ
Chen WJ. *See* Liu Y-L
Chowdari KV. *See* Talkowski ME
Chu K-W. *See* Buchsbaum MS
Clark CR. *See* Brickman AM
Clark L, Robbins TW, Ersche KD, Sahakian BJ. Reflection Impulsivity in Current and Former Substance Users, 515
Clissa P. *See* Price GW
Cohen H, Kaplan Z, Matar MA, Loewenthal U, Kozlovsky N, Zohar J. Anisomycin, a Protein Synthesis Inhibitor, Disrupts Traumatic Memory Consolidation and Attenuates Posttraumatic Stress Response in Rats, 767
Cohen LS. *See* Joffe H
Cohen RA. *See* Brickman AM
Cohn JF. *See* Pérez-Edgar K
Cooper TB. *See* Sullivan GM
Copeland PM. *See* Fan X
Coppola R. *See* Winterer G
Corcoran KA. *See* Bouton ME
Corda MG, Piras G, Giorgi O. Neonatal Ventral Hippocampal Lesions Potentiate Amphetamine-Induced Increments in Dopamine Efflux in the Core, but Not the Shell, of the Nucleus Accumbens, 1188
Corley RP. *See* Huizinga D
Cornwell B. *See* Grillon C
Corwin TE. *See* Ramoz N
Costa C. *See* Centonze D
Costa R. *See* Fyer AJ

Costello EJ. *See* Brotman MA
Courtet P. *See* Delorme R
Craft TKS, DeVries AC. Role of IL-1 in Poststroke Depressive-like Behavior in Mice, 812
Craske MG. *See* Hermans D
Csomor PA. *See* Vollenweider FX
Cubells JF. *See* Tang Y

d'Andrea I. *See* Branchi I
Daneshkhah S. *See* Otte C
Dassori A. *See* Walss-Bass C
David AS. *See* Surguladze S
David HN, Ansseau M, Lemaire M, Abraini JH. Nitrous Oxide and Xenon Prevent Amphetamine- Induced Carrier-Mediated Dopamine Release in a Memantine-Like Fashion and Protect Against Behavioral Sensitization, 49
Davidson RJ. *See* Larson CL; Schaefer HS
Davis KL. *See* Buchsbaum MS; Friedman JI, and Davis KL.
Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work, 369
DeBattista C. *See* Gomez RG
DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G. Mifepristone versus Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression, 1343
De Bellis MD, Kuchibhatla M. Cerebellar Volumes in Pediatric Maltreatment-Related Posttraumatic Stress Disorder, 697
Deep-Soboslay A. *See* Lipska BK
DelBello MP. *See* Patel NC
Delorme R, Durand CM, Betancur C, Wagner M, Ruhrmann S, Grabe H-J, Nygren G, Gillberg C, Leboyer M, Bourgeron T, Courtet P, Jollant F, Buresi C, Aubry J-M, Baud P, Bondolfi G, Bertschy G, Perroud N, Malafosse A. No Human Tryptophan Hydroxylase-2 Gene R441H Mutation in a Large Cohort of Psychiatric Patients and Control Subjects, 202
Denardin D. *See* Schmitz M
den Boer JA. *See* Reinders AS
Denicoff KD. *See* Keck PE Jr
Derks EM. *See* Boomsma DI
Deshpande S. *See* Talkowski ME
Detera-Wadleigh SD. *See* Yamada K
Detera-Wadleigh SD, McMahon FJ. G72/G30 in Schizophrenia and Bipolar Disorder: Review and Meta-Analysis, 106
Devilbiss DM. *See* Berridge CW
DeVito TJ. *See* Vidal CN
Devlin B. *See* Talkowski ME
DeVries AC. *See* Craft TKS, and DeVries AC.
Dhaliwal SK. *See* Guerriero RM
Dickey CC. *See* Koo M-S
Dickstein DP. *See* Brotman MA
Di Fausto V. *See* Branchi I
Di Paolo T. *See* Gilbert F
Ditman T. *See* Weiss AP
Doraiswamy PM. *See* Sheline YI
Doran A. *See* Morgan CA III
Doyle A. *See* Faraone SV
Doyle AE. *See* Kieling C
Drevets WC. *See* Cannon DM; Hasler G
Drost DJ. *See* Vidal CN
Duan N. *See* Keck PE Jr
Durand CM. *See* Delorme R
Durner M. *See* Fyer AJ
Durston S, Mulder M, Casey B, Ziermans T, van Engeland H. Activation in Ventral Prefrontal Cortex is Sensitive to Genetic Vulnerability for Attention-Deficit Hyperactivity Disorder, 1062
Dutton RA. *See* Vidal CN
Dyckman KA. *See* Camchong J

Ebert P. *See* Levitt P
Ebmeier KP. *See* Whalley HC
Egan MF. *See* Winterer G
Egger HL. *See* Brotman MA
Eichhammer P. *See* Sand PG
Eisch AJ. *See* Lagace DC
Eisenberger NI. *See* Taylor SE; Taylor SE
Ellis V. *See* Grillon C
Ende G. *See* Tost H
English J. *See* Meyers BS
Ernst M. *See* Roberson-Nay R
Ersche KD. *See* Clark L
Ervin JF. *See* Marx CE
Escamilla M. *See* Walss-Bass C
Evgrafov O. *See* Fyer AJ
Eyles DW. *See* Kesby JP

Faasch F. *See* Backhaus J
Fan J-B, Gu N-F, Feng G-Y, St.Clair D, He L. Reply, 664
Fan X, Anderson EJ, Copeland PM, Borba CP, Nguyen DD, Freudenreich O, Goff DC, Henderson DC. Higher Fasting Serum Insulin Is Associated with Increased Resting Energy Expenditure in Nondiabetic Schizophrenia Patients, 1372
Fann CS. *See* Liu Y-L
Faraone SV. Advances in the Genetics and Neurobiology of Attention Deficit Hyperactivity Disorder, 1025
Faraone SV. *See* Althoff RR; Biederman J; Schmitz M; Seidman LJ
Faraone SV, Biederman J, Doyle A, Murray K, Petty C, Adamson JJ, Seidman L. Neuropsychological Studies of Late Onset and Subthreshold Diagnoses of Adult Attention-Deficit/Hyperactivity Disorder, 1081
Farber NB, Nemmers B, Noguchi KK. Acute D_2/D_3 Dopaminergic Agonism but Chronic D_2/D_3 Antagonism Prevents NMDA Antagonist Neurotoxicity, 630
Fava M. *See* Fraguas R Jr; Papakostas GI; Simon NM
Fazio L. *See* Bertolino A
Feifel D. *See* Shilling PD
Feldon J. *See* Vollenweider FX
Feng G-Y. *See* Fan J-B
Ferrell RE. *See* Neumann SA
Fetissov SO, Hallman J, Nilsson I, Lefvert A-K, Oreland L, Hökfelt T. Aggressive Behavior Linked to Corticotropin-Reactive Autoantibodies, 799
Findling RL. *See* Youngstrom E
Fiore M. *See* Branchi I
Fleming SH. *See* Gomez RG
Flint AJ. *See* Meyers BS
Flores B. *See* Gomez RG; Keller J
Flory JD. *See* Neumann SA
Fox NA. *See* Pérez-Edgar K
Fraguas R Jr, Papakostas GI, Mischoulon D, Bottiglieri T, Alpert J, Fava M. Anger Attacks in Major Depressive Disorder and Serum Levels of Homocysteine, 270
Freedman R. *See* Leonard S, and Freedman R.
Freeman MP. *See* Keck PE Jr

Freudenreich O. *See* Fan X; Weiss AP
Friberg L. *See* Glenthoj BY
Friedman J. *See* Buchsbaum MS
Friedman JI, Davis KL. Special Issue: Molecular Mechanisms of Schizophrenia, 527
Frodl T. *See* Zetzsche T
Fromm SJ. *See* Cannon DM; Roberson-Nay R
Frost-Pineda K. *See* Gold MS, and Frost-Pineda K.
Frumin M. *See* Kuroki N
Frye MA. *See* Keck PE Jr
Fudge JL. *See* Rourke HO, and Fudge JL.
Fukuda Y, Koga M, Arai M, Noguchi E, Ohtsuki T, Horiuchi Y, Ishiguro H, Niizato K, Iritani S, Itokawa M, Arinami T. Monoallelic and Unequal Allelic Expression of the HTR2A Gene in Human Brain and Peripheral Lymphocytes, 1331
Fyer AJ, Hamilton SP, Durner M, Haghighi F, Heiman GA, Costa R, Evgrafov O, Adams P, Leon AB, Taveras N, Klein DF, Hodge SE, Weissman MM, Knowles JA. A Third-Pass Genome Scan in Panic Disorder: Evidence for Multiple Susceptibility Loci, 388

Gabriele M. *See* Meyers BS
Galili D. *See* Goldstein I
Gallelli K. *See* Baumer FM
Gandhi SK. *See* Cannon DM
Gao H. *See* Biederman J
Garcia K. *See* Sheline YI
Garcia R. *See* Hunt MJ; Quirk GJ
Gargus JJ. Ion Channel Functional Candidate Genes in Multigenic Neuropsychiatric Disease, 177
Geaga JA. *See* Vidal CN
Gean P-W. *See* Barad M
George MS. *See* Rush AJ, and George MS.
Gersing K. *See* Sheline YI
Geyer MA. *See* Moore H
Ghajarnia M. *See* Moore H
Ghatan PH. *See* Rydmark I
Giampietro V. *See* Surguladze S
Gilbert F, Morissette M, St-Hilaire M, Paquet B, Rouillard C, Di Paolo T, Lévesque D. *Nur77* Gene Knockout Alters Dopamine Neuron Biochemical Activity and Dopamine Turnover, 538
Gill M. *See* Bellgrove MA
Gillberg C. *See* Delorme R
Giorgi O. *See* Corda MG
Gizatullin R. *See* Zaboli G
Glass S. *See* DeBattista C
Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, Friberg L, Baaré W, Hemmingsen R, Videbaek C. Frontal Dopamine $D_{2/3}$ Receptor Binding in Drug-Naive First-Episode Schizophrenic Patients Correlates with Positive Psychotic Symptoms and Gender, 621
Goddard NH. *See* Whalley HC
Goff D. *See* Weiss AP
Goff DC. *See* Fan X
Gold MS, Frost-Pineda K. Regarding "Is Cigarette Smoking a Gateway to Alcohol and Illicit Drug Use Disorders? A Study of Youths with and without Attention Deficit Hyperactivity Disorder", 1166
Goldberg TE. *See* Winterer G
Goldstein I, Levy T, Galili D, Ovadia H, Yirmiya R, Rosen H, Lichtstein D. Involvement of Na^+; K^+-ATPase and Endogenous Digitalis-Like Compounds in Depressive Disorders, 491
Golier JA. *See* Yehuda R
Gomez RG. *See* Keller J
Gómez RG, Fleming SH, Keller J, Flores B, Kenna H, DeBattista C, Solvason B, Schatzberg AF. The Neuropsychological Profile of Psychotic Major Depression and its Relation to Cortisol, 472
González-Lima F. *See* Quirk GJ
Gordon E. *See* Brickman AM
Gorman J. *See* Buchsbaum MS
Gorman JM. *See* Sullivan GM
Gory-Fauré S. *See* Andrieux A
Goto Y, Grace AA. Alterations in Medial Prefrontal Cortical Activity and Plasticity in Rats with Disruption of Cortical Development, 1259
Gottesman II. *See* Hasler G
Gottschalk C. *See* Rasmusson AM
Gould TD. *See* Hasler G
Grabe H-J. *See* Delorme R
Grace AA. *See* Goto Y, and Grace AA.; Moore H
Grieve SM. *See* Brickman AM
Grillon C, Baas JMP, Cornwell B, Johnson L. Context Conditioning and Behavioral Avoidance in a Virtual Reality Environment: Effect of Predictability, 752
Grillon C, Baas JMP, Pine DS, Lissek S, Lawley M, Ellis V, Levine J. The Benzodiazepine Alprazolam Dissociates Contextual Fear from Cued Fear in Humans as Assessed by Fear-potentiated Startle, 760
Grossman R. *See* Yehuda R
Grotpeter J. *See* Huizinga D
Grunze H. *See* Keck PE Jr
Gu N-F. *See* Fan J-B
Guerriero RM, Hayes MM, Dhaliwal SK, Ren J-Q, Kosofsky BE. Preadolescent Methylphenidate versus Cocaine Treatment Differ in The Expression of Cocaine-Induced Locomotor Sensitization During Adolescence and Adulthood, 1171
Guidotti A. *See* Rasmusson AM
Gutnick A. *See* Sklan EH
Guyer AE. *See* Brotman MA; Roberson-Nay R

Haaksma J. *See* Reinders AS
Haberstick BC. *See* Huizinga D
Haffmans PJ. *See* Booij L
Haghighi F. *See* Fyer AJ
Hajak G. *See* Sand PG
Hajszan T, Leranth C, Roth RH. Subchronic Phencyclidine Treatment Decreases the Number of Dendritic Spine Synapses in the Rat Prefrontal Cortex, 639
Hall JE. *See* Joffe H
Hallett LA. *See* Papakostas GI
Hallman J. *See* Fetissov SO
Hallmayer J. *See* Baumer FM
Hallschmid M. *See* Wagner U
Hamilton C. *See* Berridge CW
Hamilton SP. *See* Fyer AJ
Hariri A. *See* Bertolino A
Hariri AR. *See* Neumann SA
Harral EM. *See* Pavuluri MN
Harrison PJ. *See* Tunbridge EM
Harrison PJ, Law AJ. Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology, 132
Harvey PD. *See* Yehuda R

Hasenkamp W. *See* O'Connor JA
Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK. Toward Constructing an Endophenotype Strategy for Bipolar Disorders, 93
Hattori E. *See* Yamada K
Hawi Z. *See* Bellgrove MA
Hayashi KM. *See* Vidal CN
Hayes MM. *See* Guerriero RM
Hazlett EA. *See* Buchsbaum MS
Hazlett G. *See* Morgan CA III
He L. *See* Fan J-B
Hebebrand J. *See* Holtkamp K
Hebebrand K. *See* Holtkamp K
Heckers S. *See* Weiss AP
Heerikhuize JJ. *See* Meynen G
Heilig M. *See* Rydmark I
Heiman GA. *See* Fyer AJ
Heinz A. *See* Hinckers AS
Hellsten J. *See* Jansson L
Hemby SE. *See* O'Connor JA
Hemmingsen R. *See* Glenthoj BY
Henderson D. *See* Weiss AP
Henderson DC. *See* Fan X
Hendren RL. *See* Voelbel GT
Henn FA. *See* Tost H
Henry DB. *See* Pavuluri MN
Heo M. *See* Meyers BS
Herman MM. *See* Lipska BK
Hermans D, Craske MG, Mineka S, Lovibond PF. Extinction in Human Fear Conditioning, 361
Herpertz-Dahlmann B. *See* Holtkamp K
Hewitt JK. *See* Huizinga D
Heymann-Szlachcinska A. *See* Rybakowski JK
Hicks PB. *See* Schubert MH
Higuchi T. *See* Yamada K
Hilmert CJ. *See* Taylor SE
Himmerich H, Binder EB, Künzel HE, Schuld A, Lucae S, Uhr M, Pollmächer T, Holsboer F, Ising M. Successful Antidepressant Therapy Restores the Disturbed Interplay Between TNF-α System and HPA Axis, 882
Hinckers AS, Laucht M, Schmidt MH, Mann KF, Schumann G, Schuckit MA, Heinz A. Low Level of Response to Alcohol as Associated with Serotonin Transporter Genotype and High Alcohol Intake in Adolescents, 282
Hiroi R, McDevitt RA, Neumaier JF. Estrogen Selectively Increases Tryptophan Hydroxylase-2 mRNA Expression in Distinct Subregions of Rat Midbrain Raphe Nucleus: Association between Gene Expression and Anxiety Behavior in the Open Field, 288
Ho B-C. *See* White T
Hodge SE. *See* Fyer AJ
Hof PR. *See* Buchsbaum MS
Höfle G. *See* Andrieux A
Hofman MA. *See* Meynen G
Hogan BK. *See* Saltzman W
Hohagen F. *See* Backhaus J
Hohaus K. *See* Backhaus J
Höhn F. *See* Tost H
Hökfelt T. *See* Fetissov SO
Hollander E. *See* Ramoz N
Holsboer F. *See* Himmerich H
Holtkamp K, Herpertz-Dahlmann B, Hebebrand K, Mika C, Kratzsch J, Hebebrand J. Physical Activity and Restlessness Correlate with Leptin Levels in Patients with Adolescent Anorexia Nervosa, 311
Hoogendijk WJG. *See* Meynen G
Horiuchi Y. *See* Fukuda Y
Horman BM. *See* O'Connor JA
Horne RL. *See* DeBattista C
Howe M. *See* Baumer FM
Hsieh MH. *See* Light GA; Liu Y-L
Hsu JL. *See* Light GA
Huang C-L. *See* Lane H-Y
Hudziak JJ. *See* Althoff RR; Boomsma DI
Huettner P. *See* Klein C
Huizinga D, Haberstick BC, Smolen A, Menard S, Young SE, Corley RP, Stallings MC, Grotpeter J, Hewitt JK. Childhood Maltreatment, Subsequent Antisocial Behavior, and the Role of Monoamine Oxidase A Genotype, 677
Hulette CM. *See* Marx CE
Hundemer H-P. *See* Roesch-Ely D
Hung S-I. *See* Liu Y-L
Hunt MJ, Raynaud B, Garcia R. Ketamine Dose-Dependently Induces High-Frequency Oscillations in the Nucleus Accumbens in Freely Moving Rats, 1206
Huttunen MO. *See* Ahveninen J
Hutz MH. *See* Kieling C; Schmitz M
Hwang CH. *See* Joffe H
Hwang T-J. *See* Liu Y-L
Hwu H-G. *See* Liu Y-L
Hyde TM. *See* Lipska BK

Ichise M. *See* Cannon DM
Ilmoniemi RJ. *See* Ahveninen J
Ingvar M. *See* Rydmark I
Innes-Brown H. *See* Price GW
Insel TR. *See* Anderson KC, and Insel TR.
Iritani S. *See* Fukuda Y
Ishiguro H. *See* Fukuda Y
Ishizuka K. *See* Maeda K
Ising M. *See* Himmerich H
Itokawa M. *See* Fukuda Y
Ivey J. *See* MacMaster FP
Iwayama Y. *See* Yamada K

Jääskeläinen IP. *See* Ahveninen J
Jablensky AV. *See* Price GW
Jackson CAB. *See* Larson CL
Jaeger S. *See* Roth T
Jahn H. *See* Kiefer F
Jalbrzikowski M. *See* Schechter I
Jansson L, Hellsten J, Tingström A. Region Specific Hypothalamic Neuronal Activation and Endothelial Cell Proliferation in Response to Electroconvulsive Seizures, 874
Javitt DC. *See* Schechter I
Javors MA. *See* Mitchell HA
Jentsch JD. *See* Moore H
Jiang H. *See* Young EA
Jin R. *See* Roth T
Job D. *See* Andrieux A
Joffe H, Cohen LS, Suppes T, Hwang CH, Molay F, Adams JM, Sachs GS, Hall JE. Longitudinal Follow-up of Reproductive and Metabolic Features of Valproate-Associated Polycystic Ovarian Syndrome Features: A Preliminary Report, 1378
Johnson L. *See* Grillon C

Johnson MR, Morris NA, Astur RS, Calhoun VD, Mathalon DH, Kiehl KA, Pearlson GD. A Functional Magnetic Resonance Imaging Study of Working Memory Abnormalities in Schizophrenia, 11
Johnston J. *See* Price GW
Johnstone EC. *See* Whalley HC
Jokelainen J. *See* Liukkonen T
Jollant F. *See* Delorme R
Jönsson EG. *See* Zaboli G
Jou Y-S. *See* Liu Y-L
Junghanns K. *See* Backhaus J

Kahn RS. *See* Vink M
Kalsekar A. *See* Roth T
Kaplan Z. *See* Cohen H
Kaprio J. *See* Ahveninen J
Kaufman J. Stress and Its Consequences: An Evolving Story, 669
Kaufman S. *See* Yehuda R
Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, Altshuler LL, Kupka R, Nolen WA, Leverich GS, Denicoff KD, Grunze H, Duan N, Post RM. Double-Blind, Randomized, Placebo-Controlled Trials of Ethyl-Eicosapentanoate in the Treatment of Bipolar Depression and Rapid Cycling Bipolar Disorder, 1020
Kelkar K. *See* Seidman LJ
Keller J. *See* Gomez RG
Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams GH, Schatzberg AF. Cortisol Circadian Rhythm Alterations in Psychotic Major Depression, 275
Kelley AE. *See* Berridge CW
Kellner M. *See* Otte C
Kempermann G. *See* Wolf SA
Kenis G. *See* Wichers MC
Kenna H. *See* Gomez RG; Keller J
Kennedy DN. *See* Seidman LJ
Kent A. *See* Price GW
Kesby JP, Burne THJ, McGrath JJ, Eyles DW. Developmental Vitamin D Deficiency Alters MK 801-Induced Hyperlocomotion in the Adult Rat: An Animal Model of Schizophrenia, 591
Keshavan MS. *See* MacMaster FP
Kessler RC. *See* Roth T
Khan A. *See* DeBattista C
Kiefe CI. *See* Taylor SE
Kiefer F. *See* Otte C
Kiefer F, Jahn H, Otte C, Naber D, Wiedemann K. Hypothalamic-Pituitary-Adrenocortical Axis Activity: A Target of Pharmacological Anticraving Treatment?, 74
Kiehl KA. *See* Johnson MR
Kieling C, Roman T, Doyle AE, Hutz MH, Rohde LA. Association between DRD4 Gene and Performance of Children with ADHD in a Test of Sustained Attention, 1163
Kim SS. *See* Koo M-S
Kinkead B. *See* Shilling PD
Kirley A. *See* Bellgrove MA
Klaver JM. *See* Cannon DM
Klein C, Wendling K, Huettner P, Ruder H, Peper M. Intra-Subject Variability in Attention-Deficit Hyperactivity Disorder, 1088
Klein DF. *See* Fyer AJ
Klein KL. *See* Biederman J
Klein S. *See* Tost H
Kleinman JE. *See* Lipska BK
Klimes-Dougan B, Ronsaville D, Wiggs EA, Martinez PE. Neuropsychological Functioning in Adolescent Children of Mothers with a History of Bipolar or Major Depressive Disorders, 957
Knowles JA. *See* Fyer AJ
Koek G. *See* Wichers MC
Koga M. *See* Fukuda Y
Köhnke MD. *See* Tang Y
Kolachana B. *See* Bertolino A
Kolachana BS. *See* Winterer G
Kolter T. *See* Roesch-Ely D
Koo M-S, Levitt JJ, McCarley RW, Seidman LJ, Dickey CC, Niznikiewicz MA, Voglmaier MM, Zamani P, Long KR, Kim SS, Shenton ME. Reduction of Caudate Nucleus Volumes in Neuroleptic-Naïve Female Subjects with Schizotypal Personality Disorder, 40
Korf J. *See* Reinders AS
Kosofsky BE. *See* Guerriero RM
Kovacs M. *See* Pérez-Edgar K
Kozlovsky N. *See* Cohen H
Kratzsch J. *See* Holtkamp K
Krishen A. *See* Papakostas GI
Krishnan KR. *See* Taylor WD
Krishnan KRR. *See* Bae JN
Kronenberg G. *See* Wolf SA
Krystal J. *See* Rasmusson AM
Krystal JH. Biological Psychiatry: A New Leadership Team, 794
Kubicki M. *See* Kuroki N
Kucharska-Pietura K. *See* Surguladze S
Kuchibhatla M. *See* De Bellis MD, and Kuchibhatla M.
Kujala P. *See* Andrieux A
Künzel HE. *See* Himmerich H
Kupka R. *See* Keck PE Jr
Kuroki N, Kubicki M, Nestor PG, Salisbury DF, Park H-J, Levitt JJ, Woolston S, Frumin M, Niznikiewicz M, Westin C-F, Maier SE, McCarley RW, Shenton ME. Fornix Integrity and Hippocampal Volume in Male Schizophrenic Patients, 22

LaBar KS. *See* Wang L
Lagace DC, Yee JK, Bolaños CA, Eisch AJ. Juvenile Administration of Methylphenidate Attenuates Adult Hippocampal Neurogenesis, 1121
Lal S. *See* Lepage M
Lane H-Y, Huang C-L, Wu P-L, Liu Y-C, Chang Y-C, Lin P-Y, Chen P-W, Tsai G. Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia, 645
Langguth B. *See* Sand PG
Larson CL, Schaefer HS, Siegle GJ, Jackson CAB, Anderle MJ, Davidson RJ. Fear Is Fast in Phobic Individuals: Amygdala Activation in Response to Fear-Relevant Stimuli, 410
Latorre V. *See* Bertolino A
Lattal KM, Radulovic J, Lukowiak K. 9YExtinction: Does It or Doesn't It? The Requirement of Altered Gene Activity and New Protein Synthesis, 344
Laucht M. *See* Hinckers AS
Law AJ. *See* Harrison PJ, and Law AJ.
Lawley M. *See* Grillon C
Lawrie SM. *See* Whalley HC
Leach RJ. *See* Walss-Bass C
Leboyer M. *See* Delorme R
LeDoux JE. *See* Sotres-Bayon F

Lee SFC. *See* Liu Y-L
Lefvert A-K. *See* Fetissov SO
Lehman BJ. *See* Taylor SE; Taylor SE; Taylor SE
Lehmann K. *See* Wolf SA
Lehmann ML. *See* Stone EA
Leibenluft E. *See* Brotman MA; Roberson-Nay R
Leinonen M. *See* Liukkonen T
Leinsinger G. *See* Zetzsche T
Lemaire M. *See* David HN
Leon AB. *See* Fyer AJ
Leonard S, Freedman R. Genetics of Chromosome 15q13-q14 in Schizophrenia, 115
Leopardi R. *See* Zaboli G
Lepage M, Montoya A, Pelletier M, Achim AM, Menear M, Lal S. Associative Memory Encoding and Recognition in Schizophrenia: An Event-Related fMRI Study, 1215
Leranth C. *See* Hajszan T
Leue C. *See* Wichers MC
Levant B, Radel JD, Carlson SE. Reduced Brain DHA Content After a Single Reproductive Cycle in Female Rats Fed a Diet Deficient in N-3 Polyunsaturated Fatty Acids, 987
Leverich GS. *See* Keck PE Jr
Lévesque D. *See* Gilbert F
Levine J. *See* Grillon C
Levine J, Stahl Z, Sela B-A, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker R. Homocysteine-Reducing Strategies Improve Symptoms in Chronic Schizophrenic Patients with Hyperhomocysteinemia, 265
Levinson C. *See* Petrakis IL
Levinson DF. The Genetics of Depression: A Review, 84
Levitt JJ. *See* Koo M-S; Kuroki N
Levitt P. *See* Mirnics K
Levitt P, Ebert P, Mirnics K, Nimgaonkar VL, Lewis DA. Making the Case for a Candidate Vulnerability Gene in Schizophrenia: Convergent Evidence for Regulator of G-Protein Signaling 4 (RGS4), 534
Levy T. *See* Goldstein I
Lew DF. *See* Walss-Bass C
Lewis BL. *See* Tseng KY
Lewis DA. *See* Levitt P; Maldonado-Avilés JG; Mirnics K
Lichtstein D. *See* Goldstein I
Lieberman JA. *See* Marx CE
Lieberman MD. *See* Taylor SE
Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff DL. Gamma Band Oscillations Reveal Neural Network Cortical Coherence Dysfunction in Schizophrenia Patients, 1231
Liles LC. *See* Mitchell HA
Lin C-Y. *See* Liu Y-L
Lin P-Y. *See* Lane H-Y
Lin Y. *See* Stone EA
Lipska BK, Deep-Soboslay A, Weickert CS, Hyde TM, Martin CE, Herman MM, Kleinman JE. Critical Factors in Gene Expression in Postmortem Human Brain: Focus on Studies in Schizophrenia, 650
Lissek S. *See* Grillon C
Liu C-M. *See* Liu Y-L
Liu S-K. *See* Liu Y-L
Liu W. *See* Walss-Bass C
Liu Y-C. *See* Lane H-Y
Liu Y-L, Fann CS, Liu C-M, Chen WJ, Wu J-Y, Hung S-I, Chen C-H, Jou Y-S, Liu S-K, Hwang T-J, Hsieh MH, Ouyang W-C, Chan H-Y, Chen J-J, Yang W-C, Lin C-Y, Lee SFC, Hwu H-G. A Single Nucleotide Polymorphism Fine Mapping Study of Chromosome 1q42.1 Reveals the Vulnerability Genes for Schizophrenia, *GNPAT* and *DISC1*: Association with Impairment of Sustained Attention, 554
Liukkonen T, Silvennoinen-Kassinen S, Jokelainen J, Räsänen P, Leinonen M, Meyer-Rochow VB, Timonen M. The Association Between C-Reactive Protein Levels and Depression: Results from the Northern Finland 1966 Birth Cohort Study, 825
Lo ES. *See* Sullivan GM
Loewenthal U. *See* Cohen H
Long KR. *See* Koo M-S
Lönnqvist J. *See* Ahveninen J
Lovibond PF. *See* Hermans D
Lucae S. *See* Himmerich H
Lukowiak K. *See* Lattal KM
Lurie P, Stine N. Responding to Three Articles Regarding Vagus Nerve Stimulation (VNS) for Depression, 1382
Lutz B. *See* Barad M
Lynch M. *See* MacMaster FP

MacDonald AW III, Becker TM, Carter CS. Functional Magnetic Resonance Imaging Study of Cognitive Control in the Healthy Relatives of Schizophrenia Patients, 1241
MacFall JR. *See* Bae JN
Mackeprang T. *See* Glenthoj BY
MacMaster FP, Russell A, Mirza Y, Keshavan MS, Taormina SP, Bhandari R, Boyd C, Lynch M, Rose M, Ivey J, Moore GJ, Rosenberg DR. Pituitary Volume in Treatment-Naïve Pediatric Major Depressive Disorder, 862
Maeda K, Nwulia E, Chang J, Balkissoon R, Ishizuka K, Chen H, Zandi P, McInnis MG, Sawa A. Differential Expression of Disrupted-in-Schizophrenia (DISC1) in Bipolar Disorder, 929
Maes M. *See* Wichers MC
Maier SE. *See* Kuroki N
Makris N. *See* Seidman LJ
Malafosse A. *See* Delorme R
Maldonado-Avilés JG, Wu Q, Sampson AR, Lewis DA. Somal Size of Immunolabeled Pyramidal Cells in the Prefrontal Cortex of Subjects with Schizophrenia, 226
Mangold DL, Wand GS. Cortisol and Adrenocorticotropic Hormone Responses to Naloxone in Subjects With High and Low Neuroticism, 850
Manji HK. *See* Cannon DM; Hasler G; Miller AH, and Manji HK.
Mann JJ. *See* Sullivan GM
Mann KF. *See* Hinckers AS
Manninen M. *See* Ahveninen J
Mansour H. *See* Talkowski ME
Manuck SB. *See* Neumann SA
Maren S. *See* Bouton ME
Marshall I. *See* Whalley HC
Martin CE. *See* Lipska BK
Martinez PE. *See* Klimes-Dougan B
Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC, Ervin JF, Butterfield MI, Blazer DG, Massing MW, Lieberman JA. The Neurosteroid Allopregnanolone Is Reduced in Prefrontal Cortex in Alzheimer's Disease, 1287
Maser RS. *See* Simon NM
Massing MW. *See* Marx CE
Matar MA. *See* Cohen H
Mathalon DH. *See* Johnson MR

Matthews SC. *See* Simmons A
Mattingley JB. *See* Bellgrove MA
McCarley RW. *See* Koo M-S; Kuroki N
McCarthy G. *See* Wang L
McClure EB. *See* Roberson-Nay R
McDevitt RA. *See* Hiroi R
McDowell JE. *See* Camchong J
McElroy SL. *See* Keck PE Jr
McEwan JR. *See* Steptoe A
McGrath JJ. *See* Kesby JP
McGuire KA. *See* Sponheim SR
McInnis MG. *See* Maeda K
McIntosh A. *See* Whalley HC
McMahon FJ. *See* Detera-Wadleigh SD, and McMahon FJ.
McNamara KL. *See* Simon NM
Meisenzahl EM. *See* Zetzsche T
Melendez G. *See* Shilling PD
Menard S. *See* Huizinga D
Menear M. *See* Lepage M
Mercuri NB. *See* Centonze D
Meyer-Gomes K. *See* Light GA
Meyer-Lindenberg A. *See* Bertolino A; Tost H
Meyer-Rochow VB. *See* Liukkonen T
Meyers BS, English J, Gabriele M, Peasley-Miklus C, Heo M, Flint AJ, Mulsant BH, Rothschild AJ, for the STOP-PD Study Group. A Delusion Assessment Scale for Psychotic Major Depression: Reliability, Validity, and Utility, 1336
Meyers O. *See* Youngstrom E
Meynen G, Unmehopa UA, Heerikhuize JJ, Hofman MA, Swaab DF, Hoogendijk WJG. Increased Arginine Vasopressin mRNA Expression in the Human Hypothalamus in Depression: A Preliminary Report, 892
Michie PT. *See* Price GW
Mick E. *See* Biederman J
Mika C. *See* Holtkamp K
Millar JK. *See* Porteous DJ
Miller AH, Manji HK. On Redefining the Role of the Immune System in Psychiatric Disease, 796
Minabe Y. *See* Yamada K
Mineka S. *See* Hermans D
Mintz J. *See* Keck PE Jr
Mirnics K. *See* Levitt P
Mirnics K, Levitt P, Lewis DA. Critical Appraisal of DNA Microarrays in Psychiatric Genomics, 163
Mirza Y. *See* MacMaster FP
Mischoulon D. *See* Fraguas R Jr
Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D. The Effects of Norepinephrine Transporter Inactivation on Locomotor Activity in Mice, 1046
Modell S. *See* Rydmark I
Molay F. *See* Joffe H
Möller H-J. *See* Zetzsche T
Monk CS. *See* Roberson-Nay R
Montero P. *See* Walss-Bass C
Montoya A. *See* Lepage M
Monuteaux MC. *See* Biederman J, and Monuteaux MC.; Biederman J; Seidman LJ
Moore GJ. *See* MacMaster FP
Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A Neurobehavioral Systems Analysis of Adult Rats Exposed to Methylazoxymethanol Acetate on E17: Implications for the Neuropathology of Schizophrenia, 253
Moorhead W. *See* Whalley HC
Morgan CA III, Doran A, Steffian G, Hazlett G, Southwick SM. Stress-Induced Deficits in Working Memory and Visuo-Constructive Abilities in Special Operations Soldiers, 722
Morissette M. *See* Gilbert F
Morris NA. *See* Johnson MR
Moss M. *See* Pavuluri MN
Mou X. *See* Wang C
Muhtz C. *See* Otte C
Mulder M. *See* Durston S
Mullins C. *See* Bellgrove MA
Mulsant BH. *See* Meyers BS
Muly EC. *See* O'Connor JA
Murray K. *See* Faraone SV
Murray T. *See* Shilling PD

Näätänen R. *See* Ahveninen J
Naber D. *See* Kiefer F
Nadimpalli SS. *See* Pavuluri MN
Nakatani N. *See* Yamada K
Nardini M. *See* Bertolino A
Nelson EE. *See* Roberson-Nay R
Nemeroff CB. *See* Shilling PD
Nemmers B. *See* Farber NB
Nestor PG. *See* Kuroki N
Neumaier JF. *See* Hiroi R
Neumann SA, Brown SM, Ferrell RE, Flory JD, Manuck SB, Hariri AR. Human Choline Transporter Gene Variation Is Associated with Corticolimbic Reactivity and Autonomic-Cholinergic Function, 1155
Newmark R. *See* Buchsbaum MS
Nguyen DD. *See* Fan X
Nich C. *See* Petrakis IL
Nicolson R. *See* Vidal CN
Nierenberg AA. *See* Simon NM
Niizato K. *See* Fukuda Y
Nijenhuis ERS. *See* Reinders AS
Nilsson I. *See* Fetissov SO
Nimgaonkar VL. *See* Levitt P; Talkowski ME
Niznikiewicz M. *See* Kuroki N
Niznikiewicz MA. *See* Koo M-S
Noguchi E. *See* Fukuda Y
Noguchi KK. *See* Farber NB
Nolen WA. *See* Keck PE Jr
Nugent AC. *See* Cannon DM
Nutt DJ. *See* Papakostas GI
Nwulia E. *See* Maeda K
Nygren Å. *See* Rydmark I
Nygren G. *See* Delorme R

O'Connor JA, Hasenkamp W, Horman BM, Muly EC, Hemby SE. Region Specific Regulation of NR1 in Rhesus Monkeys Following Chronic Antipsychotic Drug Administration, 659
O'Connor MM. *See* Pavuluri MN; Pavuluri MN
O'Donnell P. *See* Tseng KY
Ohba H. *See* Yamada K
Ohnishi T. *See* Yamada K
Ohtsuki T. *See* Fukuda Y
O'Leary D. *See* White T
Oquendo MA. *See* Sullivan GM
Oreland L. *See* Fetissov SO
Osher Y. *See* Levine J
Osipova D. *See* Ahveninen J
Otte C. *See* Kiefer F

Otte C, Muhtz C, Daneshkhah S, Yassouridis A, Kiefer F, Wiedemann K, Kellner M. Mineralocorticoid Receptor Function in Posttraumatic Stress Disorder After Pretreatment with Metyrapone, 784
Ouyang W-C. *See* Liu Y-L
Ovadia H. *See* Goldstein I
Overall R. *See* Wolf SA
Owens DGC. *See* Whalley HC

Paans AMJ. *See* Reinders AS
Pachoud B. *See* Andrieux A
Pakarinen S. *See* Ahveninen J
Paliwal P. *See* Rasmusson AM
Pandina G. *See* Voelbel GT
Papakostas GI. *See* Fraguas R Jr
Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors, 1350
Paquet B. *See* Gilbert F
Park H-J. *See* Kuroki N
Pasternak R. *See* Schechter I
Patel NC, DelBello MP, Cecil KM, Adler CM, Bryan HS, Stanford KE, Strakowski SM. Lithium Treatment Effects on *Myo*-Inositol in Adolescents with Bipolar Depression, 998
Paul RH. *See* Brickman AM
Paulus MP. *See* Simmons A
Paulus MP, Stein MB. An Insular View of Anxiety, 383
Pavuluri MN, Henry DB, Nadimpalli SS, O'Connor MM, Sweeney JA. Biological Risk Factors in Pediatric Bipolar Disorder, 936
Pavuluri MN, O'Connor MM, Harral EM, Moss M, Sweeney JA. Impact of Neurocognitive Function on Academic Difficulties in Pediatric Bipolar Disorder: A Clinical Translation, 951
Payne ME. *See* Bae JN
Pearlson GD. *See* Johnson MR
Peasley-Miklus C. *See* Meyers BS
Pelletier M. *See* Lepage M
Peper M. *See* Klein C
Pérez-Edgar K, Fox NA, Cohn JF, Kovacs M. Behavioral and Electrophysiological Markers of Selective Attention in Children of Parents with a History of Depression, 1131
Perkins-Porras L. *See* Steptoe A
Perroud N. *See* Delorme R
Peterson BS. *See* Wiedenmayer CP
Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Ralevski E, Rounsaville B. Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Post-Traumatic Stress Disorder, 777
Petruzzella V. *See* Bertolino A
Petty C. *See* Faraone SV
Pfeffer CR. *See* Young EA
Phelps EA. *See* Rauch SL
Phillips ML. *See* Surguladze S
Pianca T. *See* Schmitz M
Pieper C. *See* Sheline YI
Pinborg LH. *See* Glenthoj BY
Pine DS. *See* Brotman MA; Grillon C; Roberson-Nay R
Pinna G. *See* Rasmusson AM
Piras G. *See* Corda MG
Pisani A. *See* Centonze D
Pizzagalli DA. *See* Bogdan R, and Pizzagalli DA.
Poling J. *See* Petrakis IL
Pollack MH. *See* Simon NM
Pollmächer T. *See* Himmerich H
Porteous DJ, Thomson P, Brandon NJ, Millar JK. The Genetics and Biology of Disc1—An Emerging Role in Psychosis and Cognition, 123
Post RM. *See* Keck PE Jr
Prasad S. *See* Talkowski ME
Preuss UW. *See* Zetzsche T
Price GW, Michie PT, Johnston J, Innes-Brown H, Kent A, Clissa P, Jablensky AV. A Multivariate Electrophysiological Endophenotype, from a Unitary Cohort, Shows Greater Research Utility than Any Single Feature in the Western Australian Family Study of Schizophrenia, 1
Price JE. *See* Biederman J
Prosperetti C. *See* Centonze D
Putnam KM. *See* Schaefer HS

Quak J. *See* Reinders AS
Quartermain D. *See* Stone EA
Quirk GJ. Extinction: New Excitement for an Old Phenomenon, 317
Quirk GJ, Garcia R, González-Lima F. Prefrontal Mechanisms in Extinction of Conditioned Fear, 337

Radel JD. *See* Levant B
Radulovic J. *See* Lattal KM
Raemaekers M. *See* Vink M
Rajakumar N. *See* Vidal CN
Ralevski E. *See* Petrakis IL
Ramoz N, Reichert JG, Corwin TE, Smith CJ, Silverman JM, Hollander E, Buxbaum JD. Lack of Evidence for Association of the Serotonin Transporter Gene SLC6A4 with Autism, 186
Ramsey NF. *See* Vink M
Räsänen P. *See* Liukkonen T
Rasch B. *See* Wagner U
Rasmussen H. *See* Glenthoj BY
Rasmusson AM, Pinna G, Paliwal P, Weisman D, Gottschalk C, Charney D, Krystal J, Guidotti A. Decreased Cerebrospinal Fluid Allopregnanolone Levels in Women with Posttraumatic Stress Disorder, 704
Rauch SL, Shin LM, Phelps EA. Neurocircuitry Models of Posttraumatic Stress Disorder and Extinction: Human Neuroimaging Research—Past, Present, and Future, 376
Raventós H. *See* Walss-Bass C
Raynaud B. *See* Hunt MJ
Rebollo I. *See* Boomsma DI
Reichert JG. *See* Ramoz N
Reinders AS, Nijenhuis ERS, Quak J, Korf J, Haaksma J, Paans AMJ, Willemsen ATM, den Boer JA. Psychobiological Characteristics of Dissociative Identity Disorder: A Symptom Provocation Study, 730
Reiser M. *See* Zetzsche T
Ren J-Q. *See* Guerriero RM
Ressler K. *See* Davis M
Rettew DC. *See* Althoff RR; Boomsma DI
Reynolds L. *See* Sprouse J
Rich BA. *See* Brotman MA
Richardson R. *See* Davis M
Rietschel M. *See* Tost H
Robaeys G. *See* Wichers MC
Robbins TW. *See* Clark L
Roberson-Nay R, McClure EB, Monk CS, Nelson EE, Guyer AE, Fromm SJ, Charney DS, Leibenluft E, Blair J, Ernst M, Pine

DS. Increased Amygdala Activity During Successful Memory Encoding in Adolescent Major Depressive Disorder: An fMRI Study, 966
Robertson IH. *See* Bellgrove MA
Roesch-Ely D, Weiland S, Scheffel H, Schwaninger M, Hundemer H-P, Kolter T, Weisbrod M. Dopaminergic Modulation of Semantic Priming in Healthy Volunteers, 604
Rogers AK. *See* Biederman J
Rohde LA. *See* Kieling C; Schmitz M
Rollis D. *See* Cannon DM
Román GC. Vascular Depression: An Archetypal Neuropsychiatric Disorder, 1306
Roman T. *See* Kieling C; Schmitz M
Ronsaville D. *See* Klimes-Dougan B
Roose SP. *See* Sneed JR
Rose M. *See* MacMaster FP
Rosen H. *See* Goldstein I
Rosenberg DR. *See* MacMaster FP
Rossi S. *See* Centonze D
Roth RH. *See* Hajszan T
Roth T, Jaeger S, Jin R, Kalsekar A, Stang PE, Kessler RC. Sleep Problems, Comorbid Mental Disorders, and Role Functioning in the National Comorbidity Survey Replication, 1364
Rothbaum BO. *See* Davis M
Rothschild AJ. *See* Meyers BS
Rouillard C. *See* Gilbert F
Rounsaville B. *See* Petrakis IL
Rourke HO, Fudge JL. Distribution of Serotonin Transporter Labeled Fibers in Amygdaloid Subregions: Implications for Mood Disorders, 479
Rubino V. *See* Bertolino A
Rucklidge JJ. Impact of ADHD on the Neurocognitive Functioning of Adolescents with Bipolar Disorder, 921
Ruder H. *See* Klein C
Ruderman V. *See* Levine J
Ruf M. *See* Tost H
Ruhrmann S. *See* Delorme R
Rush AJ, George MS. Reply, 1382
Russell A. *See* MacMaster FP
Russell T. *See* Surguladze S
Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H. Impairment of Endothelial Function in Unipolar and Bipolar Depression, 889
Rydmark I, Wahlberg K, Ghatan PH, Modell S, Nygren Å, Ingvar M, Åsberg M, Heilig M. Neuroendocrine, Cognitive and Structural Imaging Characteristics of Women on Longterm Sickleave with Job Stress–Induced Depression, 867

Sachs GS. *See* Joffe H
Sackeim HA. *See* Sneed JR
Sahakian BJ. *See* Clark L
Salin P. *See* Andrieux A
Salisbury DF. *See* Kuroki N
Saltzman W, Hogan BK, Abbott DH. Diminished Cortisol Levels in Subordinate Female Marmosets Are Associated with Altered Central Drive to the Hypothalamic-Pituitary-Adrenal Axis, 843
Sambataro F. *See* Bertolino A
Sampson AR. *See* Maldonado-Avilés JG
Sand PG, Eichhammer P, Langguth B, Hajak G. COMT Association Data in Schizophrenia: New Caveats, 663
Saperstein AM. *See* Schechter I
Sawa A. *See* Maeda K
Saxbe D. *See* Taylor SE
Scarabino T. *See* Bertolino A
Schacter DL. *See* Weiss AP
Schaefer HS. *See* Larson CL
Schaefer HS, Putnam KM, Benca RM, Davidson RJ. Event-Related Functional Magnetic Resonance Imaging Measures of Neural Activity to Positive Social Stimuli in Pre- and Post-Treatment Depression, 974
Schatzberg AF. *See* Gomez RG; Keller J
Schechter I, Butler PD, Jalbrzikowski M, Pasternak R, Saperstein AM, Javitt DC. A New Dimension of Sensory Dysfunction: Stereopsis Deficits in Schizophrenia, 1282
Scheffel H. *See* Roesch-Ely D
Schmajuk M. *See* Brotman MA
Schmeichel B. *See* Berridge CW
Schmidt MH. *See* Hinckers AS
Schmitt A. *See* Tost H
Schmitt G. *See* Zetzsche T
Schmitz M, Denardin D, Silva TL, Pianca T, Roman T, Hutz MH, Faraone SV, Rohde LA. Association Between Alpha-2a-adrenergic Receptor Gene and ADHD Inattentive Type, 1028
Schneiderman JS. *See* Buchsbaum MS
Schoffelmeer ANM. *See* van Gaalen MM
Schubert MH, Young KA, Hicks PB. Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone, 530
Schuckit MA. *See* Hinckers AS
Schuld A. *See* Himmerich H
Schumann G. *See* Hinckers AS
Schwaninger M. *See* Roesch-Ely D
Schweitzer A. *See* Andrieux A
Seeman TE. *See* Taylor SE
Seidman L. *See* Faraone SV
Seidman LJ. *See* Koo M-S
Seidman LJ, Valera EM, Makris N, Monuteaux MC, Boriel DL, Kelkar K, Kennedy DN, Caviness VS, Bush G, Aleardi M, Faraone SV, Biederman J. Dorsolateral Prefrontal and Anterior Cingulate Cortex Volumetric Abnormalities in Adults with Attention-Deficit/Hyperactivity Disorder Identified by Magnetic Resonance Imaging, 1071
Seifert D. *See* Zetzsche T
Sela B-A. *See* Levine J
Semwal P. *See* Talkowski ME
Shahar O. *See* Sklan EH
Shampine LJ. *See* Marx CE
Shang X. *See* Wang C
Sheline YI, Barch DM, Garcia K, Gersing K, Pieper C, Welsh-Bohmer K, Steffens DC, Doraiswamy PM. Cognitive Function in Late Life Depression: Relationships to Depression Severity, Cerebrovascular Risk Factors and Processing Speed, 58
Shenton ME. *See* Koo M-S; Kuroki N
Shilling PD, Kinkead B, Murray T, Melendez G, Nemeroff CB, Feifel D. Upregulation of Striatal Dopamine-2 Receptors in Brattleboro Rats with Prepulse Inhibition Deficits, 1278
Shin LM. *See* Rauch SL
Shoham S. *See* Sklan EH
Shumaico O. *See* Levine J
Siegle GJ. *See* Larson CL
Silva TL. *See* Schmitz M

Silvennoinen-Kassinen S. *See* Liukkonen T
Silverman JM. *See* Ramoz N
Simeonova DI. *See* Baumer FM
Simmons A, Strigo I, Matthews SC, Paulus MP, Stein MB. Anticipation of Aversive Visual Stimuli Is Associated With Increased Insula Activation in Anxiety-Prone Subjects, 402
Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, Pollack MH, Nierenberg AA, Fava M, Wong K-K. Telomere Shortening and Mood Disorders: Preliminary Support for a Chronic Stress Model of Accelerated Aging, 432
Simonotto E. *See* Whalley HC
Sklan EH, Berson A, Birikh KR, Gutnick A, Shahar O, Shoham S, Soreq H. Acetylcholinesterase Modulates Stress-Induced Motor Responses Through Catalytic and Noncatalytic Properties, 741
Smith CJ. *See* Ramoz N
Smolen A. *See* Huizinga D
Smoller JW. *See* Simon NM
Sneed JR, Roose SP, Sackeim HA. Vascular Depression: A Distinct Diagnostic Subtype?, 1295
Solvason B. *See* Gomez RG
Solvason HB. *See* Keller J
Soreq H. *See* Sklan EH
Sotres-Bayon F, Cain CK, LeDoux JE. Brain Mechanisms of Fear Extinction: Historical Perspectives on the Contribution of Prefrontal Cortex, 329
Southwick SM. *See* Morgan CA III
Spencer RC. *See* Berridge CW
Spencer T. *See* Biederman J
Spencer TJ. *See* Biederman J
Sponheim SR, McGuire KA, Stanwyck JJ. Neural Anomalies During Sustained Attention in First-Degree Biological Relatives of Schizophrenia Patients, 242
Sprock J. *See* Light GA
Sprouse J, Braselton J, Reynolds L. Fluoxetine Modulates the Circadian Biological Clock via Phase Advances of Suprachiasmatic Nucleus Neuronal Firing, 896
Stahl Z. *See* Levine J
Stallings MC. *See* Huizinga D
Stanford KE. *See* Patel NC
Stang PE. *See* Roth T
Stanwyck JJ. *See* Sponheim SR
Staufenbiel M. *See* Wolf SA
St.Clair D. *See* Fan J-B
Steffens DC. *See* Bae JN; Marx CE; Sheline YI; Taylor WD
Steffian G. *See* Morgan CA III
Stein MB. *See* Paulus MP, and Stein MB.; Simmons A
Steptoe A, Strike PC, Perkins-Porras L, McEwan JR, Whitehead DL. Acute Depressed Mood as a Trigger of Acute Coronary Syndromes, 837
Stevens RD. *See* Marx CE
Stewart D. *See* Buchsbaum MS
St-Hilaire M. *See* Gilbert F
Stine N. *See* Lurie P, and Stine N.
Stone EA, Lehmann ML, Lin Y, Quartermain D. Depressive Behavior in Mice Due to Immune Stimulation is Accompanied by Reduced Neural Activity in Brain Regions Involved in Positively Motivated Behavior, 803
Strakowski SM. *See* Patel NC
Straub RE, Weinberger DR. Schizophrenia Genes - Famine to Feast, 81
Strigo I. *See* Simmons A
Strike PC. *See* Steptoe A
Suaud-Chagny M-F. *See* Andrieux A
Sui Y. *See* Vidal CN
Sullivan GM, Mann JJ, Oquendo MA, Lo ES, Cooper TB, Gorman JM. Low Cerebrospinal Fluid Transthyretin Levels in Depression: Correlations with Suicidal Ideation and Low Serotonin Function, 500
Sun J. *See* Wang C
Suppes T. *See* Joffe H; Keck PE Jr
Surguladze S, Russell T, Kucharska-Pietura K, Travis MJ, Giampietro V, David AS, Phillips ML. A Reversal of the Normal Pattern of Parahippocampal Response to Neutral and Fearful Faces Is Associated with Reality Distortion in Schizophrenia, 423
Svarer C. *See* Glenthoj BY
Swaab DF. *See* Meynen G
Sweeney JA. *See* Pavuluri MN; Pavuluri MN
Swenne CA. *See* Booij L
Swerdlow NR. *See* Light GA

Takao H. *See* Yamada K
Talkowski ME, Mansour H, Chowdari KV, Wood J, Butler A, Varma PG, Prasad S, Semwal P, Bhatia T, Deshpande S, Devlin B, Thelma B, Nimgaonkar VL. Novel, Replicated Associations Between Dopamine D3 Receptor Gene Polymorphisms and Schizophrenia in Two Independent Samples, 570
Talkowski ME, Seltman H, Bassett AS, Brzustowicz LM, Chen X, Chowdari KV, Collier DA, Cordeiro Q, Corvin AP, Deshpande SN, Egan MF, Gill M, Kendler KS, Kirov G, Heston LL, Levitt P, Lewis DA, Li T, Mirnics K, Morris DW, Norton N, O'Donovan MC, Owen MJ, Richard C, Semwal P, Sobell JL, St Clair D, Straub RE, Thelma B, Vallada H, Weinberger DR, Williams NM, Wood J, Zhang F, Devlin B, Nimgaonkar VL. Evaluation of a Susceptibility Gene for Schizophrenia: Genotype Based Meta-Analysis of RGS4 Polymorphisms from Thirteen Independent Samples, 152
Tang C. *See* Buchsbaum MS
Tang Y, Buxbaum SG, Waldman I, Anderson GM, Zabetian CP, Köhnke MD, Cubells JF. A Single Nucleotide Polymorphism at *DBH*, Possibly Associated with Attention-Deficit/Hyperactivity Disorder, Associates with Lower Plasma Dopamine β-Hydroxylase Activity and is in Linkage Disequilibrium with Two Putative Functional Single Nucleotide Polymorphisms, 1034
Taormina SP. *See* MacMaster FP
Tate DF. *See* Brickman AM
Taveras N. *See* Fyer AJ
Taylor E. *See* Brookes KJ
Taylor SE, Eisenberger NI, Saxbe D, Lehman BJ, Lieberman MD. Neural Responses to Emotional Stimuli Are Associated with Childhood Family Stress, 296
Taylor SE, Lehman BJ, Kiefe CI, Seeman TE. Relationship of Early Life Stress and Psychological Functioning to Adult C-Reactive Protein in the Coronary Artery Risk Development in Young Adults Study, 819
Taylor SE, Way BM, Welch WT, Hilmert CJ, Lehman BJ, Eisenberger NI. Early Family Environment, Current Adversity, the Serotonin Transporter Promoter Polymorphism, and Depressive Symptomatology, 671
Taylor WD. *See* Bae JN
Taylor WD, Steffens DC, Krishnan KR. Psychiatric Disease in the Twenty-First Century: The Case for Subcortical Ischemic Depression, 1299

Tenckhoff A. *See* Tost H
Thayer JF. *See* Booij L
Thelma B. *See* Talkowski ME
Therman S. *See* Ahveninen J
Thompson PM. *See* Vidal CN
Thomson P. *See* Porteous DJ
Timonen M. *See* Liukkonen T
Tingström A. *See* Jansson L
Tischler L. *See* Yehuda R
Toga AW. *See* Vidal CN
Torosjan Y. *See* Buchsbaum MS
Tost H, Meyer-Lindenberg A, Klein S, Schmitt A, Höhn F, Tenckhoff A, Ruf M, Ende G, Rietschel M, Henn FA, Braus DF. D_2 Antidopaminergic Modulation of Frontal Lobe Function in Healthy Human Subjects, 1196
Toyota T. *See* Yamada K
Travis MJ. *See* Surguladze S
Trost WT. *See* Marx CE
Tsai G. *See* Lane H-Y
Tseng KY, Amin F, Lewis BL, O'Donnell P. Altered Prefrontal Cortical Metabolic Response to Mesocortical Activation in Adult Animals with a Neonatal Ventral Hippocampal Lesion, 585
Tucker VL. *See* Papakostas GI
Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-*o*-Methyltransferase, Cognition, and Psychosis: Val^{158}Met and Beyond, 141

Uhr M. *See* Himmerich H
Unmehopa UA. *See* Meynen G
Usiello A. *See* Centonze D

Valera EM. *See* Seidman LJ
Van der Does AW. *See* Booij L
Vanderschuren LJMJ. *See* van Gaalen MM
van Engeland H. *See* Durston S
van Gaalen MM, van Koten R, Schoffelmeer ANM, Vanderschuren LJMJ. Critical Involvement of Dopaminergic Neurotransmission in Impulsive Decision Making, 66
van Koten R. *See* van Gaalen MM
Varma PG. *See* Talkowski ME
Vazquez D. *See* Young EA
Vidal CN, Nicolson R, DeVito TJ, Hayashi KM, Geaga JA, Drost DJ, Williamson PC, Rajakumar N, Sui Y, Dutton RA, Toga AW, Thompson PM. Mapping Corpus Callosum Deficits in Autism: An Index of Aberrant Cortical Connectivity, 218
Videbaek C. *See* Glenthoj BY
Villegas R. *See* Walss-Bass C
Vink M, Ramsey NF, Raemaekers M, Kahn RS. Striatal Dysfunction in Schizophrenia and Unaffected Relatives, 32
Voelbel GT, Bates ME, Buckman JF, Pandina G, Hendren RL. Caudate Nucleus Volume and Cognitive Performance: Are They Related in Childhood Psychopathology?, 942
Voglmaier MM. *See* Koo M-S
Vollenweider FX, Barro M, Csomor PA, Feldon J. Clozapine Enhances Prepulse Inhibition in Healthy Humans with Low But Not with High Prepulse Inhibition Levels, 597

Wagner M. *See* Delorme R
Wagner U, Hallschmid M, Rasch B, Born J. Brief Sleep After Learning Keeps Emotional Memories Alive for Years, 788
Wahlberg K. *See* Rydmark I
Waldman I. *See* Tang Y
Walss-Bass C, Liu W, Lew DF, Villegas R, Montero P, Dassori A, Leach RJ, Almasy L, Escamilla M, Raventos H. A Novel Missense Mutation in the Transmembrane Domain of Neuregulin 1 is Associated with Schizophrenia, 548
Wand GS. *See* Mangold DL, and Wand GS.
Wang C, Zhang Z, Sun J, Zhang X, Mou X, Zhang X, Shang X, Zhang T. Serum Free Fatty Acids and Glucose Metabolism, Insulin Resistance in Schizophrenia with Chronic Antipsychotics, 1309
Wang L, LaBar KS, McCarthy G. Mood Alters Amygdala Activation to Sad Distractors During an Attentional Task, 1139
Ward J. *See* White T
Way BM. *See* Taylor SE
Weickert CS. *See* Lipska BK
Weiland S. *See* Roesch-Ely D
Weinberger DR. *See* Bertolino A; Straub RE, and Weinberger DR.; Tunbridge EM; Winterer G
Weinshenker D. *See* Mitchell HA
Weisbrod M. *See* Roesch-Ely D
Weisman D. *See* Rasmusson AM
Weiss AP, Goff D, Schacter DL, Ditman T, Freudenreich O, Henderson D, Heckers S. Fronto-Hippocampal Function During Temporal Context Monitoring in Schizophrenia, 1268
Weissman MM. *See* Fyer AJ
Welch WT. *See* Taylor SE
Welsh-Bohmer K. *See* Sheline YI
Wendling K. *See* Klein C
Westbrook RF. *See* Bouton ME
Westin C-F. *See* Kuroki N
Whalley HC, Simonotto E, Moorhead W, McIntosh A, Marshall I, Ebmeier KP, Owens DGC, Goddard NH, Johnstone EC, Lawrie SM. Functional Imaging as a Predictor of Schizophrenia, 454
White T, Ho B-C, Ward J, O'Leary D, Andreasen NC. Neuropsychological Performance in First-Episode Adolescents with Schizophrenia: A Comparison with First-Episode Adults and Adolescent Control Subjects, 463
Whitehead DL. *See* Steptoe A
Whiteman R. *See* Wiedenmayer CP
Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M. Baseline Immune Activation as a Risk Factor for the Onset of Depression During Interferon-Alpha Treatment, 77
Widom CS, Brzustowicz LM. MAOA and the "Cycle of Violence:" Childhood Abuse and Neglect, MAOA Genotype, and Risk for Violent and Antisocial Behavior, 684
Wiedemann K. *See* Kiefer F; Otte C
Wiedenmayer CP, Bansal R, Anderson GM, Zhu H, Amat J, Whiteman R, Peterson BS. Cortisol Levels and Hippocampus Volumes in Healthy Preadolescent Children, 856
Wiggs EA. *See* Klimes-Dougan B
Wilens TE. *See* Biederman J
Willemsen ATM. *See* Reinders AS
Williams GH. *See* Keller J
Williams LM. *See* Brickman AM
Williamson PC. *See* Vidal CN
Winterer G, Egan MF, Kolachana BS, Goldberg TE, Coppola R, Weinberger DR. Prefrontal Electrophysiologic "Noise" and Catechol-*O*-Methyltransferase Genotype in Schizophrenia, 578
Wolf SA, Kronenberg G, Lehmann K, Blankenship A, Overall R, Staufenbiel M, Kempermann G. Cognitive and Physical

Activity Differently Modulate Disease Progression in the Amyloid Precursor Protein (APP)-23 Model of Alzheimer's Disease, 1314
Wong K-K. *See* Simon NM
Wood J. *See* Talkowski ME
Woolston S. *See* Kuroki N
Wu J-Y. *See* Liu Y-L
Wu P-L. *See* Lane H-Y
Wu Q. *See* Maldonado-Avilés JG
Wykretowicz A. *See* Rybakowski JK
Wysocki H. *See* Rybakowski JK

Xu X. *See* Brookes KJ

Yamada K, Hattori E, Iwayama Y, Ohnishi T, Ohba H, Toyota T, Takao H, Minabe Y, Nakatani N, Higuchi T, Detera-Wadleigh SD, Yoshikawa T. Distinguishable Haplotype Blocks in the *HTR3A* and *HTR3B* Region in the Japanese Reveal Evidence of Association of *HTR3B* with Female Major Depression, 192
Yanasak NE. *See* Camchong J
Yang W-C. *See* Liu Y-L
Yassouridis A. *See* Otte C
Yee JK. *See* Lagace DC
Yehuda R, Tischler L, Golier JA, Grossman R, Brand SR, Kaufman S, Harvey PD. Longitudinal Assessment of Cognitive Performance in Holocaust Survivors with and without PTSD, 714
Yirmiya R. *See* Goldstein I
Yoshikawa T. *See* Yamada K
Young EA, Vazquez D, Jiang H, Pfeffer CR. Saliva Cortisol and Response to Dexamethasone in Children of Depressed Parents, 831
Young KA. *See* Schubert MH
Young SE. *See* Huizinga D
Youngstrom E, Meyers O, Youngstrom JK, Calabrese JR, Findling RL. Comparing the Effects of Sampling Designs on the Diagnostic Accuracy of Eight Promising Screening Algorithms for Pediatric Bipolar Disorder, 1013
Youngstrom JK. *See* Youngstrom E

Zabetian CP. *See* Tang Y
Zaboli G, Jönsson EG, Gizatullin R, Åsberg M, Leopardi R. Tryptophan Hydroxylase-1 Gene Variants Associated with Schizophrenia, 563
Zalta AK. *See* Simon NM
Zamani P. *See* Koo M-S
Zandi P. *See* Maeda K
Zetzsche T, Frodl T, Preuss UW, Schmitt G, Seifert D, Leinsinger G, Born C, Reiser M, Möller H-J, Meisenzahl EM. Amygdala Volume and Depressive Symptoms in Patients With Borderline Personality Disorder, 302
Zhang T. *See* Wang C
Zhang X. *See* Wang C; Wang C
Zhang Z. *See* Wang C
Zhu H. *See* Wiedenmayer CP
Ziermans T. *See* Durston S
Zimmerman ME. *See* Brickman AM
Zohar J. *See* Cohen H

ne 60

and

on

th

EM.
s

S

SUBJECT INDEX TO VOLUME 60

Accelerated aging
  mood disorders and, 432
Acetylcholinesterase
  stress-induced motor responses modulated by, 741
Acute coronary syndromes
  acute depressed mood as trigger of, 837
Addiction
  cocaine effects on long-term potentiation, 436
  reflection impulsivity in, 515
Adolescents
  anorexia nervosa in, leptin levels and, 311
  with bipolar disorder
    attention-deficit/hyperactivity disorder effects on neurocognitive functioning of, 921
    myo-inositol in, lithium effects on, 998
  with major depression, amygdala activity during memory encoding in, 966
  with schizophrenia, 463
Aggressive behavior
  corticotropin-reactive autoantibodies and, 799
Aging
  white matter affected by, 444
Alcoholism
  anticraving treatment in, 74
  disulfiram for, 777
  hypothalamic-pituitary-adrenocortical axis activity and, 74
  naltrexone for, 777
  post-traumatic stress disorder patients, 777
  serotonin transporter genotype and, 282
Allopregnanolone
  cerebrospinal fluid levels of, in posttraumatic stress disorder, 704
  in prefrontal cortex of Alzheimer's disease patients, 1287
Alpha-2a-adrenergic receptor gene
  attention-deficit/hyperactivity disorder=inattentive type and, 1028
Alprazolam
  contextual fear dissociated from cued fear with, 760
Alzheimer's disease
  allopregnanolone levels of prefrontal cortex in, 1287
  amyloid precursor protein-23 model of, 1314
Amphetamine
  carrier-mediated dopamine release induced by, 49
  impulsive decision making treated with, 66
Amygdala
  activation of
    mood effects on, 1139
    secondary to fear-relevant stimuli, 410
  in extinction of conditioned fear, 322
  during memory encoding in adolescent major depression, 966
  volume of, depressive symptoms in borderline personality disorder correlated with, 302
Amygdaloid subregions
  serotonin transporter-labeled fibers in, 479
Amyloid precursor protein-23 model of Alzheimer's disease, 1314
Anger attacks in major depressive disorder
  homocysteine serum levels and, 270
Anhedonia, 1147
Anorexia nervosa
  leptin levels in, 311
Anterior cingulate cortex
  volume abnormalities, in attention-deficit/hyperactivity disorder, 1071
  white matter alterations, in late-life depression, 1356
Antibodies
  corticotropin-reactive, aggressive behavior and, 799
Antidepressants
  mania induced by, in pediatric bipolar disorder, 1005
  tumor necrosis factor-a and hypothalamic-pituitary-adrenocortical axis relationship restored with, 882
Antipsychotic drugs
  diabetes mellitus and, 1309
  NR1 regulation affected by administration of, 659
  weight gain and, 1309
Antisocial behavior
  childhood maltreatment and, 677, 684
  monoamine oxidase A genotype and, 677, 684
Anxiety disorders
  extinction research for prevention and treatment of, 319
  insula hyperactivity in, 383
  neurocircuitry models of, 376
  studies of, 383
Anxiety pronenes, 383
Arginine vasopressin mRNA
  hypothalamic expression of, in depressed patients, 892
Associative learning, 361
Associative memory encoding
  in schizophrenia, 1215
Atomoxetine
  attention-deficit/hyperactivity disorder treated with, 1106
Attention-deficit/hyperactivity disorder
  anterior cingulate cortex volumetric abnormalities in, 1071
  atomoxetine for, 1106
  DBH polymorphisms and, 1034
  DRD4 gene correlated with sustained attention test, 1163
  fatty acid desaturase genes and, 1053
  genetics of
    description of, 1025
    ventral prefrontal cortex activation and, 1062
  impulsive decision making in, 66
  inattentive type of, alpha-2a-adrenergic receptor gene association with, 1028
  intra-subject variability in, 1088
  late-onset, 1081
  morbidity associated with, 1098
  neurobiology of, 1025
  neurocognitive functioning in adolescents with bipolar disorder affected by, 921
  neuropsychological studies of, 1081
  prefrontal cortex in
    dorsolateral, 1071
    ventral, 1062
  sustained attention test in, 1163
  visual attention in, 1039
  women with, psychopathology in, 1098
Auditory-cortical dysfunction
  in schizophrenia, 612
Autism
  corpus callosum deficits in, 218
  serotonin transporter and, 186
  SLC6A4 and, 186
Autism spectrum disorders

0006-3223/06/$32.00
doi:10.1016/S0006-3223(06)01476-4

BIOL PSYCHIATRY 2006;60:1407–1414

© 2006 Society of Biological Psychiatry

cognitive performance in, caudate nucleus volume correlation with, 942
Autonomic-cholinergic function
choline transporter gene variation effects on, 1155
Aversive visual stimuli
insula activation in anxiety-prone subjects after, 402

Basal ganglia-thalamocortical circuitry disruptions
executive functioning deficits in schizophrenia associated with, 235
Behavioral avoidance
predictability effects on, 752
Benzodiazepines
contextual fear dissociated from cued fear with, 760
Bipolar depression
endothelial dysfunction in, 889
ethyl-eicosapentanoate for, 1020
Bipolar disorder
adolescent
attention-deficit/hyperactivity disorder effects on neurocognitive functioning of, 921
myo-inositol in, lithium effects on, 998
Child Behavior Checklist=Juvenile Bipolar Phenotype, 903, 912
in children
antidepressant-induced mania in, 1005
biological risk factors, 936
neurocognitive function effects on academic difficulties in, 951
neuropsychological functioning in, 957
review of, 901
screening algorithms for, 1013
DISC1 expression in, 929
endophenotype for, 93
G72/G30 in, 106
rapid cycling, ethyl-eicosapentanoate for, 1020
serotonin transporter binding in, 207
Borderline personality disorder
amygdala volume and depressive symptoms in, 302
Brain-derived neurotrophic factor
social enrichment effects on levels of, 690
Brattlebro rats
striatal dopamine-2 receptor upregulation in, with prepulse inhibition deficits, 1278
Bupropion
major depression treated with, 1350

California Verbal Learning Test, 714
Cardiovascular disease
impulsivity and, 507
Catecholamine neurotransmission
prefrontal cortex, methylphenidate effects on, 1111
Catechol-*o*-methyltransferase
description of, 141
prefrontal electrophysiologic "noise" and, 578
val158met, prefrontal-hippocampal coupling during memory processing modulated by, 1250
Caudate nucleus volume
cognitive performance correlated with, 942
in schizotypal personality disorder, 40
[11C]DASB, 207
Cerebellar volume
in childhood maltreatment-related posttraumatic stress disorder, 697
Cerebrospinal fluid
allopregnanolone levels, in posttraumatic stress disorder, 704
transthyretin levels, in depression, 500
Child Behavior Checklist=Juvenile Bipolar Phenotype
latent class analysis of, 903
longitudinal stability of, 912
Children
bipolar disorder in
antidepressant-induced mania in, 1005
biological risk factors, 936
neurocognitive function effects on academic difficulties in, 951
neuropsychological functioning in, 957
review, 901
screening algorithms for, 1013
maltreatment of
antisocial behavior and, 677, 684
monoamine oxidase A genotype and, 677, 684
posttraumatic stress disorder caused by, cerebellar volumes in, 697
mood dysregulation in, 991
severe mood dysregulation in, 991
stress experienced by
C-reactive protein levels correlated with, 819
neural responses to emotional stimuli and, 296
Choline transporter gene
corticolimbic reactivity and autonomic-cholinergic function affected by variation in, 1155
Chromosome 1q42.1, 554
Chromosome 15q13-q14
in schizophrenia, 115
Circadian rhythms
fluoxetine modulation of, 896
psychotic depression and, 275
Clozapine
glycine transporter I inhibitor and, for schizophrenia, 645
prepulse inhibition affected by, 597
Cocaine
long-term potentiation affected by, 436
methylphenidate effects on sensitivity to, 1171
Cognition
DISC1 in, 123
Cognitive control
in schizophrenia, functional magnetic resonance imaging study of, 1241
Cognitive deficits in schizophrenia
catechol-*o*-methyltransferase targeting for, 141
in first-episode adolescents, 463
galantamine effects on, 532
Cognitive function
in late life depression, 58
methylphenidate effects on, 1111
in older patients with posttraumatic stress disorder, 714
progression of amyloid precursor protein-23 Alzheimer's disease model affected by, 1314
Cognitive performance
caudate nucleus volume correlation with, 942
cortisol effects on, 472
Conditioned fear extinction
amygdala's role in, 322

behavioral and biological mechanisms of, 352
brain mechanisms of, 329
contextual modulation of, 352
prefrontal mechanisms in, 337
studies of, 361
temporal modulation of, 352
Context conditioning
predictability effects on, 752
Corpus callosum
deficits of, in autism, 218
Cortical auditory processing
in schizophrenia, 612
Corticolimbic reactivity
choline transporter gene variation effects on, 1155
Corticotrophin-releasing hormone
job stress-induced depression in women and, 867
Corticotropin-reactive autoantibodies
aggressive behavior and, 799
Cortisol
cognitive performance affected by, 472
declarative memory consolidation impairments in insomnia patients affected by, 1324
hippocampal volumes correlated with levels of, in preadolescent children, 856
hypothalamic-pituitary-adrenal axis responsiveness affected by, 843
psychotic depression and, 275, 472
saliva levels of, in children of depressed parents, 831
C-reactive protein
depression and, 825
early life stress and psychological functioning correlated with, 819
Cued fear
startle reflex to, 760
Cytochrome oxidase 1 staining, 585

DBH, 1034
D-cycloserine
extinction affected by, 369
Declarative memory consolidation
insomnia effects on, 1324
Delusion assessment scale
for psychotic major depression, 1336
Dendritic spine synapses
in prefrontal cortex, 639
Depotentiation
cocaine effects on, 436
Depression. *See also* Major depression
acute coronary syndromes and, 837
arginine vasopressin mRNA expression of hypothalamus of patients with, 892
in borderline personality disorder, amygdala volume correlated with, 302
cerebrospinal fluid transthyretin levels in, 500
in children of parents with
cortisol levels in, 831
selective attention in, behavioral and electrophysiological markers of, 1131
C-reactive protein levels correlated with, 825
endothelial dysfunction in, 889
family environment and, 671
genetics of, 84
immune stimulation effects, 803
impulsivity in, tryptophan depletion effects on, 507
interferon-alpha treatment and, 77
job stress-induced, 867
late-life
anterior cingulate cortex white matter alterations in, 1356
cognitive function in, 58
dorsolateral prefrontal cortex in, 1356
poststroke, 812
serotonin transporter gene-linked polymorphic region and, 671
social functioning and, 974
subcortical ischemic, 1299
transthyretin levels in, 500
vagus nerve stimulation for, 1382
vascular, 1295, 1304, 1306
vasopressin levels in, 892
Dexamethasone response
in children of depressed parents, 831
Diabetes mellitus
antipsychotic drugs and, 1309
Diffusion tensor imaging
in schizophrenia, 1181
Digitalis-like compounds
in mood disorders, 491
DISC1
differential expression of, in bipolar disorder, 929
in psychosis, 123
in schizophrenia, 554
Dissociative identity disorders
psychobiological characteristics of, 730
Disulfiram
alcohol dependence in post-traumatic stress disorder patients treated with, 777
DNA microarrays
psychiatric disorder genomics studied using, 163
Docosahexaenoic acid
omega-3 polyunsaturated fatty acids effect on, 987
Dopamine
frontal lobe functioning modulated by, 1196
neurotransmission
in impulsive decision making, 66
Nur77 gene knockout effects on, 538
Dopamine agonists
semantic priming modulated by, 604
Dopamine b-hydroxylase
in attention-deficit/hyperactivity disorder, 1034, 1039
Dopamine D2/3 receptor binding
agonism of, NMDA antagonist neurotoxicity prevented by, 630
in schizophrenia, 621
Dopamine D3 receptor gene polymorphisms
schizophrenia and, 570
Dorsolateral prefrontal cortex
abnormalities of, in attention-deficit/hyperactivity disorder, 1071
in late-life depression, 1356
NR1 in, 659
DRD4 gene
sustained attention test performance in attention-deficit/hyperactivity disorder correlated with, 1163

Electroconvulsive seizures

hypothalamic neuronal activation and endothelial cell proliferation in response to, 874
Emotional stimuli
neural responses to, childhood family stress and, 296
Endophenotype
for bipolar disorders, 93
for schizophrenia, 1
Endothelial cells
proliferation of, in response to electroconvulsive seizures, 874
Endothelial dysfunction
in unipolar and bipolar depression, 889
Estrogen
tryptophan hydroxylase-2 mRNA expression increased by, 288
Ethyl-eicosapentanoate
bipolar depression treated with, 1020
Event-related functional magnetic resonance imaging
associative memory encoding and recognition in schizophrenia studied using, 1215
of neural activity to positive social stimuli, 974
Executive functioning deficits
in schizophrenia
basal ganglia-thalamocortical circuitry disruptions associated with, 235
Exposure-based psychotherapy, 369
Extinction
behavioral and biological mechanisms of, 352
brain mechanisms of, 329
of conditioned fear, 322, 361
contextual modulation of, 352
D-cycloserine effects on, 369
neurocircuitry models of, 376
9Y, 344
studies of, 317, 319
temporal modulation of, 352

Facial expressions
parahippocampal response to, 527
Family environment
depression and, 671
harsh, C-reactive protein levels correlated with, 819
Fatigue
in major depression, 1350
Fatty acid desaturase genes
attention-deficit/hyperactivity disorder and, 1053
Fear
conditioned. *See* Conditioned fear
contextual, 760
cued, 760
extinction of
amygdala's role in, 322
brain mechanisms of, 329
pathologic, 410
startle reflex potentiated by, 760
Fluoxetine
circadian rhythms modulated by, 896
Fornix integrity
in schizophrenia, 22
Free fatty acids
in schizophrenia, 1309
Frontal dopamine D2/3 receptor binding
in schizophrenia, 621
Frontal lobe functioning
dopamine modulation of, 1196
Fronto-hippocampal function
during temporal context monitoring in schizophrenia, 1268
Functional magnetic resonance imaging
event-related
associative memory encoding and recognition in schizophrenia studied using, 1215
of neural activity to positive social stimuli, 974
schizophrenia evaluations
cognitive control, 1241
description of, 454
working memory abnormalities in schizophrenia studied using, 11

Galantamine
cognition in schizophrenia patients improved using, 530
Gamma band oscillations
neural network cortical coherence dysfunction schizophrenia revealed using, 1231
Gene expression
in schizophrenia, 650
G72/G30, 106
Glycine transporter I inhibitor
clozapine and, for schizophrenia, 645
GNPAT, 554
G-protein signaling 4, 152, 534

Heart rate variability
tryptophan depletion effects on, 507
High-frequency oscillations
ketamine dose inducement of, in nucleus accumbens, 1206
Hippocampus
neurogenesis in adults, early-life exposure to methylphenidate effects on, 1121
prefrontal cortex coupling with, catechol-*o*-methyltransferase val158met modulation of, 1250
volume of
cortisol levels correlated with, in preadolescent children, 856
in schizophrenia, 22
Homocysteine
anger attacks in major depressive disorder and, 270
in schizophrenia, 265
HTR2A, 1331
HTR3A, 192
HTR3B, 192
Human tryptophan hydroxylase-2 gene R441H mutation, 202
Hyperactivity
insula, in anxiety disorders, 383
leptin levels and, in anorexia nervosa adolescents, 311
Hyperhomocysteinemia
in schizophrenia, 265
Hyperlocomotion
MK 801-induced hyperlocomotion, vitamin D deficiency effects on, 591
Hypoleptinemia
in anorexia nervosa, 311
Hypothalamic-pituitary-adrenocortical axis
alcoholism and, 74
cortisol effects on responsiveness of, 843
neuroticism and, 850
in psychotic depression, 275

tumor necrosis factor-a and, antidepressant effects on relationship between, 882
Hypothalamus
arginine vasopressin mRNA expression in, of depressed patients, 892
neuronal activation, in response to electroconvulsive seizures, 874

Immune system
increased activation of, major depression risks associated with, 77
in psychiatric disease, 796
Impulsive decision making
dopaminergic neurotransmission in, 66
Impulsivity
cardiovascular disease and, 507
reflection, 515
tryptophan depletion effects on, 507
Insomnia
declarative memory consolidation impairments during, 1324
Insula
hyperactivity of, in anxiety disorders, 402
Insulin
resting energy expenditure and, 1374
Interferon-alpha
depression development associated with, 77
Interleukin-1
in poststroke depression, 812
Ion channel diseases
functional candidate genes of, 177

Job stress-induced depression, 867

KCNN3, 177
Ketamine
high-frequency oscillations in nucleus accumbens induced by, 1206

Late-life depression
anterior cingulate cortex white matter alterations in, 1356
cognitive function in, 58
dorsolateral prefrontal cortex in, 1356
Latent class analysis
of Child Behavior Checklist=Juvenile Bipolar Phenotype, 903
Learning
sleep after, effects on memory, 788
Lithium
myo-inositol levels in adolescents with bipolar disorder affected by, 998
Locomotor activity
norepinephrine transporter inactivation effects on, 1046
Locomotor sensitization
cocaine-induced, methylphenidate treatment and, 1171
Long QT syndrome, 177
Long-term memory
sleep after learning effects on, 788
Long-term potentiation
cocaine effects on, 436

Magnetic resonance imaging. *See* Functional magnetic resonance imaging
Major depression. *See also* Depression
adolescent, amygdala activity during memory encoding in, 966
anger attacks in, homocysteine serum levels and, 270
bupropion for, 1350
in children of parents with
cortisol levels in, 831
selective attention in, behavioral and electrophysiological markers of, 1131
cortisol levels and, 831
fatigue in, 1350
genetics of, 84
human tryptophan hydroxylase-2 gene R441H mutation and, 202
increased immune activation as risk factor for, 77
pituitary volume in, 862
psychotic
cortisol circadian rhythm alterations in, 275
delusion assessment scale for, 1336
neuropsychological profile of, 472
psychosis in, mifepristone for, 1343
sleepiness in, 1350
in women, *HTR3A* and *HTR3B* in, 192
Mania, pediatric
antidepressant-induced, 1005
studies of, 901
Medial prefrontal cortical activity
impairments in, 1259
Memantine
amphetamine-induced carrier-mediated dopamine release affected by, 49
Memory
sleep after learning effects on, 788
Memory encoding
amygdala activity during, in adolescent major depression, 966
associative, in schizophrenia, 1215
Memory processing
catechol-*o*-methyltransferase val158met modulation of prefrontal-hippocampal coupling during, 1250
Methylazoxymethanol acetate on E17, 253
Methylphenidate
catecholamine neurotransmission in prefrontal cortex increased using, 1111
cocaine sensitivity and, 1171
early-life exposure to, adult hippocampal neurogenesis attenuated by, 1121
Metyrapone
mineralocorticoid receptor function in posttraumatic stress disorder affected by, 784
Microarrays
psychiatric disorder genomics studied using, 163
Microtubule stabilizer
synaptic function and behavior in schizophrenia affected by, 1224
Midbrain raphe nucleus
tryptophan hydroxylase-2 mRNA expression in, 288
Mifepristone
psychosis in psychotic major depression treated with, 1343
Mineralocorticoid receptor
in posttraumatic stress disorder, metyrapone effects on, 784
Monoamine oxidase A genotype
childhood maltreatment and antisocial behavior, 677, 684
Monogenic seizure syndromes, 177

Mood
amygdala activation affected by, 1139
Mood disorders
accelerated aging and, 432
digitalis-like compounds in, 491
Na+,K+-ATPase involvement in, 491
serotonin transporter-labeled fibers in amygdaloid subregions, 479
telomere shortening and, 432
Mood dysregulation
in children, 991
Motor responses, stress-induced
acetylcholinesterase modulation of, 741
Myo-inositol
lithium effects on, in adolescents with bipolar disorder, 998

Na+,K+-ATPase compounds
in mood disorders, 491
Naloxone
cortisol and adrenocorticotropic hormone responses to, in neuroticism, 850
Naltrexone
alcohol dependence in post-traumatic stress disorder patients treated with, 777
National Comorbidity Survey Replication, 1364
Neonatal ventral hippocampal lesions
amphetamine-induced increments in nucleus accumbens shell and core potentiated by, 1188
description of, 585
Nerve growth factor
social enrichment effects on levels of, 690
Neural network cortical coherence dysfunction
gamma band oscillations used to reveal, in schizophrenia, 1231
Neuregulin 1
missense mutation in transmembrane domain of, 548
schizophrenia and, 132
Neurocognitive functioning
attention-deficit/hyperactivity disorder effects on, in adolescents with bipolar disorder, 921
Neurofilament protein, 226
Neuronal calcium binding protein-1, 226
Neuropsychological functioning
in adolescents with first-episode schizophrenia, 463
in pediatric bipolar disorder
academic difficulties associated with, 951
studies of, 957
regional white matter and, 444
Neuroticism
cortisol and adrenocorticotropic hormone responses to naloxone in, 850
9Y extinction, 344
Nitrous oxide
amphetamine-induced carrier-mediated dopamine release affected by, 49
NMDA antagonists
neurotoxicity of, dopamine D2/3 agonism effects on, 630
NMDA receptors
activation of, in nucleus accumbens, 49
Nonphosphorylated neurofilament protein, 226
Norepinephrine transporter
locomotor activity affected by, 1046
NR1, 659
Nucleus accumbens
ketamine dose-induced high-frequency oscillations in, 1206
neonatal ventral hippocampal lesion potentiation of amphetamine-induced increments in shell and core of, 1188
NMDA receptor activation in, 49
Nur77, 538

Omega-3 polyunsaturated fatty acids
docosahexaenoic acid levels in brain affected by, 987

Panic disorder
genetic susceptibility to, 388
Parahippocampal response
to facial expressions, 527
Pathological fear, 410
Pavlovian conditioning
extinction of, 317
Periodic paralysis, 177
Phencyclidine
dendritic spine synapses in prefrontal cortex decreased with, 639
Physical activity
leptin levels in anorexia nervosa correlated with, 311
progression of amyloid precursor protein-23 Alzheimer's disease model affected by, 1314
Pituitary volume
in major depression, 862
Polycystic ovarian syndrome
valproate-associated, 1378
Positive behavior
immune stimulation effects on, 803
Positron emission tomography
serotonin transporter binding in bipolar disorder studied using, 207
Poststroke anhedonia, 812
Posttraumatic stress disorder. *See also* Stress
alcohol dependence and, disulfiram and naltrexone for, 777
anisomycin effects on, 767
cerebrospinal fluid allopregnanolone levels in, 704
childhood maltreatment-related, cerebellar volumes in, 697
cognitive performance in Holocaust survivors with and without, 714
metyrapone pretreatment, mineralocorticoid receptor function after, 784
neurocircuitry models of, 376
traumatic memory consolidation in, 767
Predictability
context conditioning affected by, 752
Prefrontal cortex
allopregnanolone levels in, of Alzheimer's disease patients, 1287
catecholamine neurotransmission in, methylphenidate effects on, 1111
catechol-*o*-methyltransferase effects on, 141
in conditioned fear extinction, 337
cytochrome oxidase 1 staining, 585
dendritic spine synapses in, phencyclidine effects on, 639
dopamine signaling in, 1196
dorsolateral
abnormalities of, in attention-deficit/hyperactivity disorder, 1071
in late-life depression, 1356

NR1 in, 659
electrophysiologic "noise," catechol-*o*-methyltransferase and, 578
fear extinction and, 329, 337
hippocampal coupling with, catechol-*o*-methyltransferase val158met modulation of, 1250
immunolabeled pyramidal cells in, of schizophrenia patients, 226
metabolic response alterations, to mesocortical activation, 585
semantic priming, 604
ventral, attention-deficit/hyperactivity disorder genetics and, 1062
Prepulse inhibition
clozapine effects on, 597
deficits, striatal dopamine-2 receptor upregulation in rats with, 1278
Psychiatric disorders
DNA microarrays in, 163
immune system's role in, 796
Psychosis
DISC1 in, 123
Psychotic depression
cortisol circadian rhythm alterations in, 275
delusion assessment scale for, 1336
hypothalamic-pituitary-adrenocortical axis in, 275
neuropsychological profile of, 472
psychosis in, mifepristone for, 1343
Pyramidal cells
in prefrontal cortex of schizophrenia patient, 226

Reflection impulsivity, 515
Regional white matter
neuropsychological functioning and, 444
Resting energy expenditure
serum insulin levels and, 1374
Restlessness
leptin levels in anorexia nervosa correlated with, 311
Reward responsiveness
acute stress effects on, 1147
RGS4, 152, 534
R441H, 202
Risperidone
schizophrenia treated with, 530

Schizophrenia
in adolescents, 463
antipsychotic drugs for, 1309
associative memory encoding and recognition in, 1215
auditory-cortical dysfunction in, 612
candidate vulnerability gene in, 534
chromosome 1q42.1 in, 554
chromosome 15q13-q14, 115
clozapine and glycine transporter I inhibitor for, 645
cognitive control in, functional magnetic resonance imaging study of, 1241
cognitive deficits in
catechol-*o*-methyltransferase targeting for, 141
in first-episode adolescents, 463
galantamine for, 530
cognitive processing in, 1169
cortical auditory processing abnormalities in, 612
diffusion tensor imaging in, 1181
DISC1 in, 554
dopamine D3 receptor gene polymorphisms and, 570
emotional processing in, 1169
endophenotype of
description of, 1
sustained attention deficit as, 242, 554
executive functioning deficits in
basal ganglia-thalamocortical circuitry disruptions associated with, 235
fornix integrity in, 22
free fatty acid levels in, 1309
frontal dopamine D2/3 receptor binding in, 621
functional magnetic resonance imaging of, 11, 454
gene expression in, 650
genetic factors
animal studies of, 1259
description of, 81
striatal abnormalities and, 32
G72/G30 in, 106
glycine transporter I inhibitor and clozapine for, 645
GNPAT in, 554
hippocampal volume in, 22
HTR2A and, 1331
with hyperhomocysteinemia, homocysteine-reducing strategies for, 265
methylazoxymethanol acetate on E17 rodent models of, 253
microtubule stabilizer effects on synaptic function and behavior in, 1224
missense mutation in transmembrane domain of neuregulin 1 and, 548
molecular mechanisms of, 527
neural network cortical coherence dysfunction in, gamma band oscillations used to reveal, 1231
neuregulin 1 and, 132, 548
neuropathology of, 253
parahippocampal response to neutral and fearful faces, 527
postmortem studies of, 650
prefrontal cortex, somal size of immunolabeled pyramidal cells in, 226
reality distortion in, 527
resting energy expenditure in, 1374
RGS4 and, 152, 534
risperidone for, 530
stereopsis deficits in, 1282
striatal dysfunction in, 32
susceptibility gene for, 152
sustained attention in, neural anomalies during, 242, 554
synaptic function and behavior in, 1224
temporal context monitoring in, fronto-hippocampal function during, 1268
tryptophan hydroxylase-1 gene variants associated with, 563
vitamin D deficiency and, 591
working memory abnormalities in, 11
Schizotypal personality disorder
caudate nucleus volumes in women with, 40
Seizures, electroconvulsive, 874
Selective attention
behavioral and electrophysiological markers of, 1131
Selective serotonin reuptake inhibitors
circadian rhythms modulated by, 896
major depression treated with, 1350
Semantic priming
dopaminergic modulation of, 604

Serotonin transporter
antidepressant-linked mania in pediatric bipolar disorder and, 1005
in autism, 186
binding, in bipolar disorder, 207
genotype, alcohol response correlated with, 282
labeled fibers, in amygdaloid subregions, 479
Serotonin transporter gene-linked polymorphic region
depression and, 671
Severe mood dysregulation
in children, 991
SLC6A4, 186
Sleep
comorbid mental disorders and, 1364
declarative memory consolidation impairments during insomnia, 1324
after learning, effects on memory, 788
Social behavior
social enrichment effects on, 690
Social enrichment
brain-derived neurotrophic factor levels affected by, 690
nerve growth factor levels affected by, 690
social behavior affected by, 690
Social functioning
depression and, 974
Startle reflex
fear-potentiated, 760
Stereopsis deficits
in schizophrenia, 1282
STOP protein, 1224
Stress. *See also* Posttraumatic stress disorder
acetylcholinesterase modulation of motor responses induced by, 741
childhood
C-reactive protein levels correlated with, 819
neural responses to emotional stimuli and, 296
consequences of, 669
reward responsiveness affected by, 1147
visuo-constructive abilities affected by, 722
working memory deficits secondary to, 722
Striatal dopamine-2 receptor
upregulation of, in prepulse inhibition deficits, 1278
Striatum
in schizophrenia, 32
Stroke
depression after, 812
Subcortical ischemic depression, 1299
Substance abuse
reflection impulsivity in, 515
Suicidal ideation
cerebrospinal fluid transthyretin levels and, 500
Suprachiasmatic nucleus, 896
Susceptibility genes
for panic disorder, 388
for schizophrenia, 152
Sustained attention deficit
in attention-deficit/hyperactivity disorder children, 1163
in schizophrenia, 242, 554

Telomere shortening
mood disorders and, 432
Thyroid axis dysfunction
suicidal ideation and, 500
Transthyretin
cerebrospinal fluid levels of, in depression, 500
Traumatic memory
anisomycin effects on, 767
Tryptophan depletion
heart rate variability and impulsivity affected by, 507
Tryptophan hydroxylase-1 gene
schizophrenia and, 563
Tryptophan hydroxylase-2 mRNA expression
estrogen effects on, 288
Tumor necrosis factor-a
hypothalamic-pituitary-adrenocortical axis and, antidepressant effects on relationship between, 882

Vagus nerve stimulation, for depression, 1382
Valproate-associated polycystic ovarian syndrome, 1378
Vascular depression, 1295, 1304, 1306
Virtual reality environment
context conditioning and behavior avoidance in, 752
Visual attention
in attention-deficit/hyperactivity disorder, 1039
Visuo-constructive abilities
stress-induced deficits in, 722
Vitamin D deficiency
MK 801-induced hyperlocomotion affected by, 591

Weight gain
antipsychotic drugs and, 1309
White matter
age-associated decline in, 444
anterior cingulate cortex, in late-life depression, 1356
neuropsychological functioning and, 444
Women
attention-deficit/hyperactivity disorder in, psychopathology associated with, 1098
caudate nucleus volumes in schizotypal personality disorder, 40
job stress-induced depression in, 867
major depression in, *HTR3A* and *HTR3B* in, 192
Working memory
schizophrenia-related abnormalities in functional magnetic resonance imaging study of, 11
stress-induced deficits in, 722

Xenon
amphetamine-induced carrier-mediated dopamine release affected by, 49